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     Anaphylaxis is a severe life-threatening allergic condition which has dramatically 
increased in prevalence in recent years and now affects more than 2% of UK children. 
Anaphylaxis management requires the avoidance of allergen triggers and preparation in 
readiness for an emergency, i.e., for an anaphylactic reaction. People with anaphylaxis and 
their carers carry Adrenaline Auto-Injectors which need to be administered immediately in 
the event of an anaphylactic reaction. But, unfortunately, many people often do not know 
how to use the injectors and fail to use them or fail to use them correctly. This is due in part 
to deficiencies in training and also to a lack of a system encouraging continuous practice and 
providing feedback on that practice.   
   Pervasive healthcare research has demonstrated potential in supporting the management of 
chronic conditions such as diabetes, cardiovascular disease and asthma. However, research 
into assistive technology applications for the support of anaphylaxis management has been 
significantly neglected. 
   This thesis sought to answer three research questions: What assistive smartphone tools have 
potential to supplement anaphylaxis management? Could a smartphone tool improve 
adrenaline injection performance in training and positively influence self-efficacy, and what 
is the clinical evaluation of allergy specialists regarding the use and deployment of such 
tools?. 
     The research used a multi-stage prototype methodology that evolved prototypes from 
design to laboratory proof-of-concept and on toward a smartphone and wireless sensor near-
clinical proof-of-concept prototype with expert clinical evaluation. The functionality, 
usability and ease-of-use of prototypes were assessed, and, the final system, AllergiSense, 
was designed with participatory design and the embedding of self-efficacy sources. The 
randomised, controlled testing of AllergiSense is presented with results demonstrating 
significantly improved injection training skills and a positive influence on self-efficacy. In 
addition, the results provide insights into possible self-efficacy failings in traditional training 
and benefits of embedding self-efficacy into the design process. The thesis also summarises 
qualitative evaluation from interviews with clinical staff who were provided AllergiSense for 
one week and which expressed positive feedback regarding the potential of the technology.  
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     This research was motivated by the increasing prevalence of life-threatening anaphylaxis 
(Gupta et al., 2007; Lieberman et al. 2006; Lin et al., 2008; Poulos et al., 2007; Sheikh & 
Alves, 2000; Sheikh & Strachan, 2003; Simon & Mulla, 2008) and the ambition to support 
improved anaphylaxis management, in particular, to improve on the poor performance of 
Adrenaline Auto-Injector (AAI) use (Arga et al., 2011; Diwakar 2010; Pumphrey, 2011). 
Advances in pervasive and assistive health technology research have contributed toward 
improved management of other chronic health conditions (Free et al., 2013; Fjeldsoe et al., 
2009; Belisario et al., 2013), but anaphylaxis has been neglected (Vavoula & Lonsdale, 2007). 
This is unfortunate because people with anaphylaxis really need good management skills to 
avoid life-threatening allergic reactions and to respond correctly in the event of such a 
reaction (NICE, 2011). Additionally, people with anaphylaxis and their carers are motivated 
more than most to carry mobile phones because they may need to make emergency calls, and 
so the technology needed for a pervasive healthcare solution is already available. 
 
    The following sections of this chapter introduce subjects relevant to this thesis, namely, 
anaphylaxis and its management, anaphylactic people’s unmet needs and self-efficacy theory. 
This chapter also outlines the research questions, the contribution to knowledge and the 




                               




     “Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death” 
(Sampson et al., 2006:392). Reactions may occur rapidly after contact, ingestion or inhalation 
of an allergen which may be a food, a wasp or bee sting, or a substance such as latex or a 
prescription drug (Lieberman et al., 2005). Reactions to allergens can also be delayed and can 
occur several hours after exposure (Ellis & Day, 2007). The Anaphylaxis Campaign UK 
(2010) explains that reactions occur when “the body's immune system reacts inappropriately 
in response to the presence of a substance that it wrongly perceives as a threat”. Not 
surprisingly, anaphylaxis has implications not just for the individual affected but also for their 
family and friends. For example, “invitations to dinner parties and social gatherings become 
a source of embarrassment and anxiety rather than enjoyment. A simple trip to the 
supermarket can become a lengthy series of food label examinations and a family trip abroad, 
if even considered, a delicate military operation” (Sherwood, 2007:6) 
 
     The National Institute for Health and Care Excellence (NICE) in the UK (2011) has 
reported a lack of robust figures on anaphylaxis prevalence due, in part, to misdiagnosis and 
ambiguity in reporting, for example, cases of anaphylaxis reported as allergy or asthma. 
Anaphylaxis significantly affects developed countries (Sicherer & Sampson 2010) with an 
increase in occurrence that has elicited debate of an epidemic magnitude (Simons & Sampson, 
2008). Gold & Sainsbury (2000) reported anaphylactic reactions with a frequency of 0.98 
events per anaphylactic person per year and The Anaphylaxis Campaign UK (2010) has 
reported that around a million people in the UK suffer from anaphylaxis and as many as one in 
52 children have anaphylaxis in the UK, i.e., that 2% of all children are now anaphylactic. For 
younger children, severe allergic reactions occur mostly in the home, while for adults, 
reactions occur more often outside the home (e.g., at parties, family gatherings, at restaurants 
and on flights) (Clark & Ewan, 2008; Jaervinen, 2011; Sicherer & Sampson, 2010).  
 
     The Royal College of Physicians (2003) suggests that severe allergic reactions are probably 
caused by environmental factors acting on a genetic predisposition. In addition, the “Hygiene 
Hypothesis” (Strachan, 1989), highlights the fact that declining family size, better household 
amenities, and improved standards of personal cleanliness have contributed to a reduction in cross 
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infections in young families and a missing opportunity to educate their immune systems to 
recognise and handle real threats. 
 
     According to the World Allergic Organisation (Kemp et al., 2008) an allergic reaction 
involves an abrupt release of chemical substances such as histamine from cells in the blood. 
The substances are released because of the reaction between the allergen and an antibody 
(e.g., Immunoglobulin E or Immunoglobulin G), and this mechanism is so sensitive that it can 
be caused by minute quantities of the allergen. The released substances affect the blood 
vessels to cause allergic symptoms. These can be mild symptoms such as itchy nose, flushing 
or rashing of the skin, headache or they can be more severe such as swelling of throat and 
mouth, difficulty in swallowing or speaking, change in voice, alterations in heart rate, severe 
asthma, abdominal pain, vomiting, a sudden drop in blood pressure or loss of consciousness 
(Allergy UK, 2011; Kemp et al., 2008; The Anaphylaxis Campaign UK, 2010). In people 
with anaphylaxis, allergic symptoms can be so severe that they can cause death (Sampson et 
al., 2006). 
 
     The reported mortality caused by anaphylaxis varies widely per country and per study. For 
example, the World Allergic Organisation (2006) has reported that approximately 29,000 
food-anaphylactic events occur each year in the USA, resulting in approximately 2,000 
hospitalisations and 150 deaths. However, a higher USA mortality rate has been estimated by 
Tang (2003) as approximately 1,500 deaths per year. Moneret-Vautrin et al. (2005) reported 
anaphylactic death rates of 0.65-2% while, in a meta-study, Umasunthar et al. (2013) 
estimated fatal food anaphylaxis rates at less than those due to accidental death. Pumphrey 
(2000) reported only 20 fatal anaphylactic reactions per year in the UK, but anaphylactic 
deaths are under-reported (Pumphrey, 2004). They can be difficult to identify and may be 
misreported as respiratory distress or cardiac arrest (Brown, Mullins & Gold, 2006).  
 
     The World Allergy Organisation (2009) and The Anaphylaxis Campaign UK (2010) report that 
the most common triggers of anaphylaxis “include foods such as peanuts, tree nuts (e.g., almonds, 
walnuts, cashews, brazil nuts), sesame, fish, shellfish, dairy products and eggs. Non-food causes 
include wasp or bee stings”, pollens, animals (e.g., contact with cats or dogs), latex and 
prescription medicines (e.g., penicillin). Reactions can be exacerbated by non-immunological 
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mechanisms, for example, exercise, sun exposure, air temperature and medication (Sheikh, 
2011).  
 
     Foods are the most common allergens for children, adolescents and young adults but for 
older people, non-food allergens such as prescription medications and insect stings, are more 
common (Simons et al, 2011). Children frequently develop tolerance to milk, egg, soya and 
wheat allergens by school age, however, allergies to nuts and shellfish are more likely to be 
lifelong (Allen, Hill & Heine, 2006).  
 
     The first-line treatment for an anaphylactic reaction is the immediate administration of 
adrenaline (epinephrine) given by a pre-loaded Adrenaline Auto-Injector (AAI) (e.g., 
Epipen©, Jext®, etc.) into the outer thigh (NICE, 2011). The injection must be given “as soon 
as a serious reaction is suspected and an ambulance must be called” (Anaphylaxis Campaign 
UK, 2010) and if symptoms do not improve in five to ten minutes a second injection should 
be given (ibid; Muraro et al., 2007). Adrenaline is used because “during anaphylaxis, blood 
vessels leak, bronchial tissues swell and blood pressure drops, causing choking and/or 
collapse. Adrenaline acts quickly to constrict blood vessels, relax muscles in the lungs to 
improve breathing, increase heart rate and help to stop swelling around the face and lips” 
(Anaphylaxis Campaign UK, 2010). Anaphylactic people and their carers should carry one or 
more AAIs (RCPCH, 2008; Kemp et al., 2008; Lieberman et al., 2010) and also a mobile 
phone to call emergency services and alert family or friends in the event of a reaction (Simons 
et al., 2011). 
 
1.3    Anaphylaxis management and unmet needs 
     Following a first anaphylactic event, patients typically meet with a family doctor or 
clinician, who may make a referral for diagnosis and advice on managing their allergies and 
preventing reactions (Ewan & Clark, 2005). Patients should then be provided with AAIs and 
trained in their use (NICE 2011; Royal College of Physicians, 2003). This is usually done by 
family doctors, allergy specialists, allergy nurses or pharmacists (Xu et al., 2010). The AAIs 
are packaged with patient information leaflets showing how they are used. Further 
information documents may be provided to the patients or they may obtain them themselves, 
for example, on-line resources of AAI manufacturers or allergy support groups such as the 
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Anaphylaxis Campaign UK or Allergy UK. We refer to this conventional style of care, 
learning, training and support as the “traditional” care system.  
 
     Since reactions might be provoked by inhalation, ingestion or skin contact with minute 
amounts of an allergen, and so can be unpredictable (Pumphrey, 2004), it is important that 
people at risk learn about anaphylaxis management. The management of anaphylaxis requires 
allergen avoidance and emergency preparedness (Walker & Sheikh, 2003; Wang, 2010; 
NICE, 2011; Simons et al., 2011). Allergen avoidance requires careful inspection of 
ingredients in food product labels to look for allergens (Walker & Sheikh, 2003; Umasunthar 
et al., 2013) as well as awareness of contamination risks, for example, ensuring food has not 
been cut with a knife that has been in contact with an allergen. Emergency preparedness 
involves training in the use of AAIs (Simons, 2009), wearing medical identification (Muraro 
et al., 2007) and having an emergency Allergy Action Plan: a plan that provides a summary of 
symptoms, emergency actions including AAI use, allergy details and emergency contacts 
(BSACI, 2014; NICE 2011; Royal College of Physicians, 2003).  
 
     Unfortunately, people with anaphylaxis have unmet needs and lack satisfactory levels of 
anaphylaxis management (Royal College of Physicians, 2003). After initial medical advice 
there may be little further reinforcement or support of the necessary on-going learning and 
management processes beyond the traditional care documents available to the patient. Warner 
et al. (2006) has reported a global lack of specialists, the need for improved patient care, 
training and expertise in this area, and the lack of appropriate clinical services to support 
people with anaphylaxis. Xu et al. (2010) has reported a lack of training for nurses and school 
staff. Carlisle (2010) has reported that patients can find allergen-free eating difficult and may 
not have an Allergy Action Plan or fail to follow it or fail to have an AAI available at the time 
of a severe reaction. Xu et al. (2010) has reported that training can be delayed or incomplete 
and that only a minority of families feel confident avoiding allergens and knowing when and 
how to use an AAI, and that they do not receive enough information about their allergies or 
about support groups. Kastner, Harada & Waserman (2010) have observed that the 
management of anaphylaxis is inadequate and, in particular, that little attention has been given 
to the long-term management aspects of the condition. For example, there can be a lack of 
access to AAIs and specialist advice, a lack of preventive strategies for patients and carers and 
                               
 Chapter 1. Introduction 
6 
 
a lack of education and training in diagnosis and treatment and a lack of consistent 
information about management.  
     Pumphrey (2000; 2004) reported that very poor outcomes in anaphylaxis involve, 
avoidance failure (e.g., rules broken, risks taken, contamination and cross contamination), 
poorly controlled asthma (co-morbidity), and, during a reaction, failure to lie down (the 
patient should lie down with legs raised), inhalation of vomit after giving adrenaline, incorrect 
use, delay or reluctance (perhaps caused by embarrassment) in the injection of adrenaline and 
delay in making the emergency call.  
     The correct use of AAIs is significant in anaphylaxis management (Lieberman et al., 
2010). However, there are significant gaps in use, practice and training (Arga et al., 2011; 
Brown et al., 2013; Carlisle, 2010; Diwakar, 2010; Gallagher et al., 2011; Luckhurst et al., 
2013; Macadam et al., 2012; Mehr, Robinson & Tang, 2007; Nguyen et al., 2012; Noimark et 
al., 2012; Sicherer, Forman & Noone, 2000). Many patients and carers do not know how to 
use AAIs (Diwakar, 2010; Sicherer, Forman & Noone, 2000), either because they were not 
trained correctly at the outset or they did not have a system of continuous practice and forgot 
(Sicherer, Forman & Noone, 2000). For example, Brown et al. (2013) found that a 
concerningly low percentage of only 15% of 100 mothers could inject an AAI properly after 
being shown how to do it. Similarly, in a comparison of three AAIs from different 
manufacturers with 120 adults and children over 12 years old with no experience in their use, 
Luckhurst et al. (2013) found that regardless of the type of injector, only 28% of the 
participants performed all the injections steps correctly. Likewise, in a randomised study 
carried out in a Canadian school settings with 343 staff participants who had attended 
training, Nguyen et al. (2012) found that only 26.3% of the participants (the best of three 
groups involved) demonstrated a good performance. Additionally, Noimark et al. (2012) 
found that of 245 paediatric allergy patients who reported anaphylactic reactions in the 
previous year, only 41 used an AAI. The commonest reasons for not using an AAI were that 
they ‘thought adrenaline unnecessary’ (54.4%) and were ‘unsure adrenaline necessary’ 
(19.1%) other reasons included that they had already called an ambulance or that they went to 
an emergency department, that an AAI was not available, they were afraid to use it, were not 
trained to use it, or that it had expired. Similarly, Gallagher et al. (2011) interviewed 26 
adolescents and 28 parents and identified that main barriers to AAI use were failure to 
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recognise anaphylactic symptoms, uncertainty about the injection steps and fear of using the 
AAI. In addition, Macadam et al. (2012) interviewed 20 anaphylactic teenagers and observed 
that most were making quite complex risk decisions about carrying their AAIs but noted that 
not all decisions were rational. Some teenagers reported not carrying their AAI because of 
concerns about size of the AAI and how it looks, uncertainty about its use and the hassle of it, 
e.g., managing the AAI expiry date and temperature (adrenaline should be stored at room 
temperature – it can degrade if, for example, it is stored in a fridge or in a hot car). 
   Unfortunately, it is not only users who have difficulties with AAI use. Many physicians, 
including paediatricians, are not familiar with AAIs (Arga et al., 2011; Sicherer, Forman & 
Noone, 2000). For example, Mehr, Robinson & Tang (2007) have suggested that the reason 
parents and children cannot use their AAIs may be because their doctors do not know how to 
demonstrate correct use. The authors recruited 100 doctors including residents, registrars and 
consultants (half of them had already prescribed an AAI), but unfortunately only 2% of them 
correctly demonstrated all the injection steps. Even after reading the injection steps, only 41% 
were able to demonstrate the steps correctly and one in five doctors self-injected their finger. 
Similarly, Arga et al. (2011) found in a study with 151 general physicians, residents and 
consultants that only 35 (23 %) were able to demonstrate how to use an AAI before receiving 
extra training. Typical injection errors can include: not injecting with enough force, carrying 
out unintentional self-injections and not holding the AAI in the site of the injection for the 
required time (Carlisle, 2010).  
     Although new AAI brands have appeared on the market and there have been some 
proposals to improve adrenaline injections e.g., modifying AAI design and labelling (Bakirtas 
et al., 2011; Gosbee, 2004) or simplifying the steps required (Kranke et al., 2011), there is, as 
yet, no ideal solution (Arga et al., 2012). Meanwhile, the consensus recommended in the 
clinical literature is that training should be improved and should ensure correct injection 
techniques are used and that training is continuous, monitored and assessed so that skills are 
refreshed and maintained in readiness for emergency events (Bina et al., 2006; Brown et al., 
2013; Frew, 2011; Macadam et al. 2012;  Mehr et al., 2007; NICE, 2011; Nguyen et al., 2012; 
Noimark et al., 2012). The proposal made in this thesis is the use of technology to provide 
supplementary support of anaphylaxis management, and in particular, the maintenance and 
monitoring of AAI training. 
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1.4 Self-efficacy theory 
     Glanz & Bishop (2010) observed that health-promotion interventions grounded on social 
and behavioural science theories are more effective than those not having a theoretical base. 
The design and evaluation phases of this thesis were informed by Bandura’s (1977) self-
efficacy theory. Self-efficacy refers to the “beliefs in one’s capabilities to organize and 
execute the courses of action required to produce given levels of attainments” (Bandura, 
1998:624). In other words, self-efficacy is related to the beliefs that one person has to carry out 
specific activities and behaviours in order to achieve their goals. This theory was used because 
evidence suggests that self-efficacy is a significant predictor of behavioural change and the 
levels and duration of sustained effort that a person invests in a task or behaviour (Bandura, 
1997). Self-efficacy is also a major contributor to performance; it affects levels of motivation, 
perseverance, goal setting, outcome expectations, emotional states, vulnerability to stress and 
depression, and optimistic or pessimistic points of view (Bandura, 2012). Self-efficacy can be 
modified by four sources of information (Bandura, 1977): from enactive experience (i.e., 
experiencing attainment through mastery and practice), from vicarious experience (i.e., 
modelling other people having success in challenging activities), from social persuasion (i.e., 
receiving encouraging or discouraging information from other people) and from the perception 
of one’s physiological states (i.e., the interpretation of one’s physiological responses as 
indicators of personal competency). 
 
     Once a goal is achieved, people with “high self-efficacy set even higher goals for them- 
selves and mount a vigorous effort to realize these goals; those of somewhat lower efficacy 
believe they can achieve the original goal, stick to it, and work a bit harder; and those who 
distrust their efficacy to even repeat what they had accomplished lower their goals and slacken 
their efforts” (Bandura, 2012:18). In this way, self-efficacy is a significant predictor of 
adherence to management plans, for example, plans for the self-management of chronic 
conditions (Lorig and Holman, 2003). Where medical or healthcare self-management is the 
individual’s ability to manage their medical condition, its treatment and the physical and 
emotional consequences that result from it (Barlow et al., 2001). And where patients and carers 
themselves take a central role, with responsibility moving away from the healthcare system 
and towards themselves (Von Korff et al. 1997). Self-management is fundamental to good 
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anaphylaxis management so that people with anaphylaxis can take control of their condition 
and its consequences.  
     The reason for including self-efficacy theory in this research was that helping improve 
adrenaline injection performance and patient self-efficacy could translate to better 
anaphylaxis management. More specifically, higher levels of self-efficacy, together with 
improved training may imply better injection skills, better preparedness, improved confidence 
and, potentially, better outcomes in the self-management of anaphylaxis. 
 
1.5 Research questions 
     The three research questions of this thesis arose from the hypothesis that pervasive 
healthcare technology, informed by self-efficacy theory could provide opportunities to 
support adrenaline injection training and anaphylaxis management; an application which 
presents challenges but could offer significant rewards but, as yet, has been little supported by 
pervasive healthcare technology.  The research questions of this thesis are: 
 
1) What assistive smartphone tools have potential to supplement anaphylaxis 
management? 
The objective of this question was to map the needs of anaphylaxis management onto possible 
technology solutions: Firstly, investigating the tools needed for anaphylaxis management 
according to the needs presented in clinical literature and from anaphylactic people, carers 
and allergy specialists. And secondly, investigating the feasibility and usability of 
management tools implemented in functional smartphone prototypes. 
 
2) Could a smartphone tool improve adrenaline injection performance in training and 
positively influence self-efficacy?  
Adrenaline injection performance is a key component of anaphylaxis management. This 
research question addresses the potential effect of technology (smartphone tools and wireless 
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3) What is the clinical evaluation of specialists regarding the use and deployment of such 
tools? 
The objective of this research question was to investigate the opinions of allergy specialists 
(clinicians and allergy nurses) toward the use of everyday and emergency smartphone tools 
for anaphylaxis management. 
 
1.6 Contribution to knowledge 
The contribution of this thesis is three-fold:  
 It defines tools desirable in the support of anaphylaxis management. 
 It provides evidence about the ability of smartphone tools to improve AAI training 
and positively affect injection self-efficacy. 
 It provides evidence of support from expert clinical evaluation regarding use and 
deployment. 
     First, this thesis argues that smartphone tools, informed by self-efficacy theory, may have 
the potential to enhance adrenaline injection training by supplementing the traditional care 
documents. And second, that clinical specialists can have positive attitudes towards the use of 
smartphone tools for anaphylaxis management and their possible deployment in patient 
settings. 
     The contribution of this thesis involved the use of a “multi-stage prototyping” 
methodology proposed in (Matthews et al., 2008). This methodology was used because it 
integrates the iterative approach suggested by Human-Centred Design (ISO 9241-210, 2010); 
the production of usable prototypes proposed by the “Clinical Proof of Concept (CPoC)” 
methodology (Bardram, 2008); and the involvement of healthy volunteers as per phase zero 
clinical trials (NHS, 2012). The methodology involved three stages: design of the smartphone 
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1.7 Thesis structure  
This thesis is organised as follows:  
     Chapter 2 reviews the relevant literature. It summarises pervasive healthcare research aims, 
opportunities and challenges and comprises research examples of mobile devices for the 
management of chronic diseases including diabetes, cardiovascular disease and asthma. Later, 
pervasive healthcare applications and online smartphone "apps" for anaphylaxis management 
are discussed. And, at the end of the chapter, self-efficacy theory, its benefits and examples of 
research involving this theory are reviewed   
     Chapter 3 presents the design and evaluation of a series of multi-stage proof-of-concept pre-
clinical laboratory prototypes (PervaLaxis 1-3). The needs of people regarding anaphylaxis 
management are identified from the clinical literature and from workshops organised by a 
support group. Results from laboratory usability studies and from a pilot evaluation of 
smartphone adrenaline injection training tools are presented and discussed.  
     Chapter 4 provides details of the AllergiSense design; a clinical proof-of-concept prototype 
created in participatory design focus groups with allergy specialists, anaphylactic people and 
carers. Design stages explained in this chapter comprised group brainstorming exercises, paper 
prototyping and paper mock ups. Additionally, an algorithm for wireless adrenaline injection 
sensing is explained.  
     Chapter 5 presents the results of a three-arm, pre-post, randomised, controlled study aimed 
at identifying and quantifying the benefits that AllergiSense smartphone tools may have to 
enhance adrenaline injection training and AAI self-efficacy, in comparison with traditional 
care paper documents.  
      Chapter 6 shows results of a qualitative companion study with clinicians who were 
provided with AllergiSense technology for at least one week. Results include opinions and 
attitudes of the allergy specialists about smartphone technologies for anaphylaxis management 
and about their deployment in patient settings. 
      Finally, chapter 7 summarises the conclusions of this research and discusses future work 
issues and directions.  
 










     “Pervasive healthcare may be defined from two perspectives: first, as the application of 
pervasive computing—or ubiquitous computing, proactive computing, ambient intelligence— 
technologies for healthcare, health, and wellness management; second, as making healthcare 
available everywhere, anytime— pervasively. Essentially, pervasive healthcare addresses 
those technologies and concepts that integrate healthcare more seamlessly into our everyday 




     This chapter presents a review of the literature relevant to mobile devices in pervasive 
healthcare. To provide a context for this thesis, because there has been almost no pervasive 
healthcare research applied to anaphylaxis, the review includes research supporting the 
management of other chronic diseases. The chapter also reviews self-efficacy and its 
application to healthcare and anaphylaxis management. 
 
2.2 Pervasive healthcare – opportunities and challenges 
     Pervasive healthcare ambitions include the design and deployment of solutions to enhance 
healthcare outcomes by providing healthcare to “anyone, anytime and anywhere” (Bardram, 
2008; Varshney 2003; Varshney 2007), with solutions for both clinicians and patients, and 
described by Jakob Bardram as follows: 
 




     “Pervasive healthcare encompasses research on ubiquitous technologies both for 
supporting clinicians working in a hospital or other health institutions, as well as patients—
and more generally citizens—themselves. The goal in the former case is to create 
technologies that help clinicians better treat and care for patients; in the latter case that 
patients become more capable and resourceful in their own disease management. Pervasive 
healthcare technologies can of course also be a hybrid of these two types of systems—that is, 
having systems that help patients manage health-related issues in close cooperation with 
clinical staff at a hospital.” (Bardram, published in Dey & Estrin, 2011:4) 
 
     Medical care has evolved over time from physicians visiting patients in their own homes 
to a more centralised model where clinicians and medical equipment are concentrated in 
hospitals and clinics (Arnrich et al., 2010). However, this centralised model faces significant 
challenges from the increasing costs and care quality demands made by populations that are 
aging and in which chronic conditions such as diabetes, arthritis and cardiovascular diseases, 
have increased in prevalence (Dall et al., 2013; Lehnert et al., 2011) have become leading 
causes of death (WHO, 2014). Pervasive healthcare has been proposed as means to enable a 
shift away from the centralised healthcare model toward a User-Centred model supporting 
proactive and preventative health management (Arnrich et al., 2010). However, this vision of 
pervasive healthcare presents technological, methodological and administrative challenges 
(Arnrich et al., 2010). The technological challenges include the development of devices that 
are intuitive and easy-to-use; the development of reliable infrastructure and interoperable 
systems to support seamless communication between different devices and networks; and the 
development of security technologies and mechanisms to protect confidential data (Varshney, 
2007). Methodology challenges include the development of procedures that provide 
standardised, reliable and comparable results in controlled and uncontrolled environments 
(Bardram, 2008). And administrative challenges include the ethical and regulatory challenges 
involved in developing, evaluating and certifying solutions (Varshney, 2007). 
 
2.3 Evaluation, prototyping and participatory design methodologies in 
pervasive healthcare research 
     In clinical studies the evaluation of a medicine or a treatment is typically carried out in 
staged clinical trial phases (NHS, 2013). Phase zero trials (early research) assess the effects of 
a new treatment on small numbers of healthy human subjects. Phase one trials (dose-ranging 




studies) involve a small number of people, who may be healthy participants, to determine safe 
dosages and identify side effects. Phase two trials are short-term studies which test the 
effectiveness of the new treatment (usually compared with a placebo) on larger groups. With 
good results from phases one and two, phase three trials can proceed. Phase three trials involve 
longer-term evaluations with large groups of patients taking the medicine or acting as controls 
taking an existing treatment or placebo. Phase four (post-marketing) trials continue 
investigating safety, side effects and effectiveness of the treatment while it is being used in 
practice.  
 
     Clinical trials are expensive, long-term endeavours which require substantial commitment 
to legal and regulatory processes. Before a clinical trial can begin a research protocol must be 
submitted and approved by a specialised Research Ethics Committee (REC), funding must be 
secured, liability insurance obtained, a hospital or a research institute must agree to provide a 
home base for the study and researchers must obtain certification (e.g., good clinical practice 
certificates) and access permissions (research passports). For studies involving medical device 
technologies which may be commercial progenitors, Medicines and Healthcare products 
Regulatory Agency (MHRA) processes must also be followed. This long-term investment in 
formal testing is at odds with the rapid evolution of advances in mobile technology and also in 
user expectation. Years invested in formal testing may well provide important clinical 
evaluation, but the technology may then be out-dated and users may not want to use it.  If the 
tested system were updated to a more current platform, and possibly improved with 
functionality provided by that platform, then the old evaluation may have no relevance. 
 
     Much of the early research in pervasive healthcare has involved the production of 
laboratory (or technological) proof-of-concept systems which has provided useful evidence to 
support the technological feasibility of the approach but has done little to further future 
clinical application. The creation of a new academic journal, IEEE Journal of Translational 
Engineering in Health and Medicine (JTEHM, 2014) focusing on the “intersection of 
engineering and clinical translation” evidences the need for work at the boundary to translate 
engineering technology into clinical practice with effective outcomes. 
 
     In pervasive healthcare research a methodology involving a “Clinical Proof-of-Concept” 
(CPoC) has been recommended as a compromise between the two extremes; clinical trials 
and laboratory proof-of-concepts (Bardram, 2008; 2010). The recommendation being that the 




CPoC is a working usable prototype and is evaluated by real users for an appropriate amount 
of time (possibly one to three months) ibid. Though, of course, access to “real users”, i.e., to 
patients, involves rigorous, complex and time-consuming clinical study permissions similar 
to those involved in clinical trials and which pose substantial obstacles to individual 
researchers and small research teams. 
 
      In early stage research, where there is no working prototype, “multi-stage prototyping” 
methodology has been proposed (Matthews et al., 2008; Doherty, Coyle & Matthews, 2010). 
The methodology involves three stages: Focus group, peer study and clinical evaluation. 
These stages overlap with the iterative approach recommended by the Human-Centred 
Design standard (ISO 9241-210, 2010), the production of usable prototypes proposed in the 
CPoC methodology (Bardram, 2008), and the involvement of healthy volunteers 
recommended for phase zero and phase one clinical trials (NHS, 2013). The focus group 
stage comprises the use of qualitative research such as interviews, focus groups and direct 
observation to create paper and working prototypes, and to carry out usability evaluations. 
Participatory design, i.e., design with the participation of users, designers and programmers 
(Muller, Wildman & White, 1993) can also benefit the design of working prototypes. User 
participation can benefit design by improving the quality of the proposed solution (Muller, 
1991) and improving user satisfaction (Kujala, 2003). The peer study stage involves 
assessment of prototypes with small groups of healthy participants. And the clinical 
assessment stage consists of evaluating a working prototype in collaboration with clinical 
specialists. 
 
2.4 Pervasive healthcare with mobile devices  
     The following sections review mobile device examples of pervasive healthcare for chronic 
health conditions
1
. While some of the examples include deployments of the technology in 
clinical trials and provide evidence of clinical effectiveness, the majority of the literature 
presents research outcomes that are much less mature. For example, evaluations are frequently 
limited to feasibility and usability studies of laboratory proof-of-concepts or involve limited 
assessment of short–term outcomes. And, as mentioned earlier, there is very little in the 
literature relevant to the self-management of anaphylaxis supported by pervasive healthcare 
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. While, in contrast, there are myriad healthcare “apps” for which there is often little 
or no evidence of formal evaluation.  
 
2.4.1 Supporting well-being and healthcare 
     In a review of assistive mobile phone applications, Blake (2008) observed promising 
results across a broad range of healthcare interventions including dietary management, 
promotion of physical activity and smoking cessation; and opportunities in chronic disease 
management, in particular for health monitoring in cancer, asthma, diabetes and dementia. 
Challenges reported included support for people less familiar with mobile technology or for 
people with low literacy. Blake observed that more evidence is needed regarding the 
effectiveness of these interventions and the long-term impact of mobile applications on health 
outcomes, health knowledge, healthcare delivery and changes in lifestyle behaviours.  
 
   Detailed usability results for three health promotion applications were reported by Athinen 
et al. (2009). The study was notable for being controlled and randomised and having a large 
sample size. One-hundred and nineteen technology participants (Finnish public-service 
employees) were provided with three mobile applications: a wellness diary (for self-
observation of weight, exercise and steps taken), a mobile coach (for physical activity 
support) and a relaxation program. Participants reported some habit changes and the feedback 
was generally positive. The technology was generally perceived as intuitive, motivating and 
effective, but required a learning period, was sometimes monotonous, complicated or 
inconvenient and, in parts, lacked persuasion. The users liked the ability to observe progress 
over time but wanted adaptive, easy-to-use interfaces and applications with flexible schedules 
of use (allowing for gaps in use, for example, over weekends, busy times or during holidays). 
 
   In a review of mobile phone text message reminders for treatment adherence, Fjeldsoe, 
Marshall & Miller (2009) identified positive short-term behavioural outcomes in 13 of 14 
randomised controlled trials. These included positive behaviours for smoking cessation, 
physical activity, anti-obesity behaviour modification, bulimia nervosa care and the self-
management of diabetes, asthma and hypertension. However, the authors concluded that 
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much more research is required to build on the “first generation studies”, many of which were 
pilot tests or feasibility studies. They recommended improved research methodologies (they 
particularly noted a lack of theory-based interventions) and the testing of intervention 
efficacy with larger samples. 
 
     In a systematic review of smartphone applications for healthcare, Mosa, Yoo & Sheets 
(2012) classified solutions from the literature according to their functionality. They 
documented a total of 83 applications: 57 for medical professionals and 15 for patients. The 
former were grouped in seven categories according to their functionality, for example, for 
drug diagnosis, as medical calculators, as drug reference applications, for clinical 
communication or for medical training. While the latter included smartphone solutions for the 
management of chronic conditions, for patient monitoring and for patient education. The 
authors concluded that smartphone applications have potential in healthcare settings but that 
more research is needed to investigate clinical benefit. The authors also concluded that 
“smartphones can play a very important role in patient education, disease self-management, 
and remote monitoring of patients”. They observe that the work of healthcare professionals is 
very mobile in nature and that the functionality of applications is growing day by day and that 
“the full potential of smartphones has yet to be exploited”. They also observed that a 
substantial amount of medical applications are available for download in online web sites 
such as Google Play or Apple’s App stores, but note that most of them have not been 
analysed in the clinical literature.  
 
2.4.2 Supporting diabetes management  
     Diabetes is a chronic condition that has received much attention in pervasive healthcare. 
Diabetes is a metabolic condition affecting blood sugar levels. Type I diabetes is the less 
common form and occurs when insulin, the regulating hormone, is not created by the body. 
Type II diabetes (known as insulin resistance) is much more prevalent and takes place when 
not enough insulin is produced or when there is a failure of cells to respond to this hormone. 
Gómez et al. (2008) developed the INCA (Intelligent control assistant for diabetes) system 
which provides an example of pervasive healthcare research evolving from the development 
of a laboratory prototype through to feasibility evaluation with small sample sizes and on to 
larger scale evaluation. INCA used a PDA with GPRS communication, an insulin pump and a 
glucose measurement device and could be used by patients as an “artificial pancreas”, 
calculating the dose of insulin according to glucose readings. In addition, the PDA provided 




information to the patient (e.g., glucose level visualisations) and sent data for clinical review 
(e.g., current insulin dosage, glucose levels, diet and health data). The feasibility of the 
system and the clinical effect were evaluated in separate studies. In the first study, four 
patients with type I diabetes used the system and reported very high levels of satisfaction, but 
experienced technical issues with data transmission, mobile coverage and battery 
consumption. The second study involved a cross-over clinical trial with ten type I diabetic 
patients. Patients used the system for four weeks then had a control period of four weeks 
without the system. Improvements in participant blood glucose levels were observed during 
the intervention and patients reported that they felt more secure in managing their diabetes 
while using the system.  
 
     In a randomised controlled study Faridi et al. (2008) evaluated the impact of a mobile 
phone intervention with 30 type II diabetic patients over three months. The solution, called 
NICHE (i.e., Novel Interactive Cell-phone technology for Health Enhancement) implemented 
tailored text message feedback and reminders to participants. Intervention patients attended a 
one-day technology training workshop and were asked to measure their blood glucose levels 
and upload these together with pedometer data once a day. Control patients received no 
additional support but did count their steps with a pedometer. Lower, but non-significant, 
blood glucose levels were observed in the intervention group but only 25% of intervention 
patients used the system for at least 75% of the time. Faridi et al. reported that non-significant 
intervention effects were possibly due to the small sample size of the study and the low 
utilisation of the system, likely due to usability issues and user inexperience with the 
pedometer and the mobile phone.  
      
     Feasibility studies on diabetes management with mobile devices are frequent in the 
literature. For example, Yung-Hsiu et al. (2009) evaluated a PDA system supporting diabetic 
patients. The PDA was connected to a set of physiological measurement devices to quantify 
blood glucose, blood pressure and body weight. The system was used by 27 type II diabetic 
participants for one month. However, though the study used technology acceptance 
questionnaires for system usefulness, ease-of-use and attitudes towards, it was limited to 
investigating the viability of sending physiological data to a care centre and there was no 
control group. In common with other studies, positive reactions regarding the technology 
were obtained but no outcomes, clinical or otherwise, were evaluated.  
 




   In a feasibility study entitled “Enhanced 911/GPS Wizard for the Prevention of Severe 
Hypoglycaemia-Monitor, Alert and Locate” Dassau et al. (2009) described the idea of a 
smartphone alarm with GPS and Google maps online links to send automated text messages 
to physicians and emergency services about people experiencing low and very low blood 
glucose levels. They implemented staged alarm functionality depending upon the severity of 
the glucose readings. However, their test data was limited to glucose levels in clinical records 
and no real testing or evaluations with participants were made.  
 
2.4.3 Supporting the management of cardiovascular diseases  
     Since cardiovascular diseases are a major cause of death (WHO, 2014), their management 
and support is a significant concern in healthcare and they have continued, from the outset, to 
be of interest in pervasive healthcare research. For example, in a technological proof-of-
concept Hong et al. (2007) developed a ZigBee® wireless three-channel electrocardiogram 
(ECG) with a three-axial accelerometer. Data were transmitted to a remote server using a 
personal digital assistant (PDA), where medical specialists could observe and analyse the 
data. In an early clinical proof-of-concept system Salvador et al. (2005) utilised a mobile 
phone with Internet connectivity for cardiac out-patient follow-up. They evaluated the 
technology with 89 patients who had the system for 50 days. Patients collected physiological 
data (ECG, blood pressure, pulse oximetry and weight) depending upon their risk group. 
Results indicated that use of a mobile phone to transmit physiological out-patient data was 
feasible. However, the study had a number of limitations such as not having a control group, 
comprising only participants in stable conditions and not evaluating health outcomes.  
 
     In a five-year randomised controlled clinical trial called MOBITEL, Scherr et al. (2009) 
evaluated the impact of mobile phone devices on outcomes (hospitalisation and mortality) of 
chronic heart failure patients. Fifty-four patients were allocated to a control group receiving 
pharmacological treatment for six months, while another 54 patients in a “tele-group” (the 
intervention group) received pharmacological treatment and medical surveillance via a 
mobile phone for six months. Tele-group patients measured their blood pressure, heart rate 
and body weight daily and used the phone to send these together with medication dosage 
information to a monitoring centre. Physicians could analyse the data and call patients if 
necessary. Physicians could also receive email and text message notifications when data 
surpassed specified limits. Results showed that patients in the control group had more 
negative events (1 death, 17 hospitalisations) compared with the tele-group (0 deaths, 11 




hospitalisations); and that tele-group patients spent significantly less time in hospital. 
However, the authors of the study reported difficulties with some patients, particularly elderly 
patients, in managing the materials (the mobile phone, weight scale and sphygmomanometer) 
and performing the necessary measurements.  
 
2.4.4 Supporting dementia 
     Pervasive healthcare research has been active in the support of mental health, in particular, 
in the support of people with dementia. For example, a multidisciplinary European FP6 
consortia, COGKNOW Mulvenna et al. (2007;2010), researched and developed pervasive 
healthcare technologies for people with mild dementia. Their aim was to develop a system for 
the elderly to help them remember to take their medicine, to maintain social contact with their 
relatives and carers, and to support the activities of daily living and feelings of safety with a 
variety of reminders and warnings, for instance, reminding them to take their keys and their 
mobile phone with them when leaving home. COGKNOW prototype development included 
four main components: sensors placed in the home (e.g., on the fridge and on the doors) for 
activity monitoring; a tablet computer for assistance in the home (e.g., picture dialling, 
reminders and for listening to the radio); a handheld device for assistance outside the home 
(e.g., for telephony and location services) and a location monitor (with a service for carers 
and relatives providing status information about the person with dementia). The results of the 
COGKNOW study showed that elderly people with mild to moderate dementia could make 
use of, and obtain benefit from, handheld devices, and that their involvement in the design 
process improved the outcomes in terms of meeting their needs.  
  
     Another example of technology support for dementia was presented by Taub et al. (2011). 
They described “The Escort” system and its twelve-week study evaluation in a care home. 
The Escort monitors people suffering from Alzheimer’s disease and informs carers about 
potentially unsafe locations or situations that may cause an accident. For example, passing 
through specific doors to exit the building. Selected patients based on mobility level and 
incident history wore LED ZigBee®-networked badges to report their location. Carers could 
be alerted of possible risky situations via automatic SMS messages with information about 
the patient’s context. Although the system appeared to work as expected in an actual patient’s 
residence, slow transmission of location information (the pagers used by carers took between 
90 to 120 seconds to receive messages, while a mobile phones takes 5 to 10 seconds to 
receive a message) resulted in a delay in the carer response. Additionally, there were some 




issues with battery life and with usability (device size and comfortability). But despite the 
challenges, with elderly populations increasing, this technology could have significant future 
benefits if, for example, more patients could be monitored with fewer carers and if the 
incidence of risky situations could be decreased. 
 
2.4.5 Supporting the management of asthma 
   Asthma is a common chronic inflammatory disease of the airways. It is commonly 
comorbid (i.e., co-occurs with a primary disease) with anaphylaxis and significant in poor 
anaphylaxis outcomes (Pumphrey, 2004). For example, a study in children found that 90% of 
those who died from anaphylaxis had asthma (Lee & Vadas, 2011).  
 
     A number of pervasive health studies have investigated how mobile phones might support 
people with asthma. For example, Chu, Huang, Lian, & Tsai (2006) demonstrated 
technological feasibility with a proof-of-concept system for asthma management. It included 
the use of a PDA with GPS receiver to check local air quality. The PDA connected to a web 
server that consulted air quality stations, and the web server was able to return warning 
messages to the user’s PDA. Nevertheless, this study was limited to recorded data from 
pollution-reporting stations and participants were not neither in design nor in testing.  
Similarly, in a month-long feasibility study, Holtz & Whitten (2009) tested mobile phone 
support of asthma treatment. Patients submitted their peak flow readings and could view 
charts of their readings over time. Participants received text message reminders to send their 
readings and confirmation messages with an action plan in case of abnormal readings. While 
participants reported good levels of satisfaction, usefulness and effectiveness, the study was 
limited in terms of viability with a sample size of only four patients. In a more thorough 
evaluation, Ryan et al. (2005) carried out a nine-month observational study using an 
electronic peak flow monitor connected to a mobile phone. Ninety-one patients including 
children and adults were asked to measure peak flows in the morning and afternoon and send 
their readings via the mobile phone. Users received prompt reading feedback with peak flow 
trends of their readings graphed over time. A helpline was also available to provide 
personalised feedback to patients. Participants indicated the system helped them to manage 
their symptoms, improve their awareness of asthma and their self-monitoring skills. Good 
levels of utilisation were found, and the system was perceived as a valuable tool. However, 
its use presented a level of technical inconvenience such as loss of battery power and GPRS 




connectivity; and lacked a control group to provide a comparison with traditional asthma self-
management programs, to which adherence has been often low (Clatworthy et al., 2009).  
 
     Continuing with Ryan et al’s. (2005) work, Cleland, Caldow & Ryan (2007) carried out 
semi-structured interviews with 12 participants after they used a similar system (a mobile 
phone connected to a peak flow monitor) for 40 weeks. Their results indicated that the mobile 
phone technology was perceived as convenient, especially when wireless technology such as 
Bluetooth
TM
 was used; patients felt more aware of their asthma symptoms and perceived the 
system as being a more accurate mechanism for recording and transmit peak flow readings. 
However, although this study provided good insights about participants’ opinions, it lacked a 
control group and did not measure clinical outcomes.  
 
   In an effort to evaluate clinical outcomes, Ryan et al., (2012) carried out a six-month 
randomised clinical trial with 288 teenagers and adults, comparing a mobile phone 
application with a paper-based method for monitoring peak flow and control of asthma. But 
contrary to expectations, they found no significant differences in asthma outcomes. For 
example, both groups experienced improvements, similar number of exacerbations and 
unscheduled consultations; but with the technology group’s care being more expensive. The 
authors suggest their results could be due to both groups receiving the same initial 
educational intervention, which, in other studies, is often less intensive for the control group. 
The study did not report on usefulness and ease-of use of the technology; important factors 
that can affect the long-term acceptance of interventions (Davis, 1989).  
 
     Pinnock et al. (2006) and Holtz & Whitten (2009) have suggested that future studies of 
pervasive healthcare technologies for asthma monitoring and control should involve 
evaluations with patients and practitioners and involve non-invasive methods of tele-
monitoring breathing (e.g., using breath sound) to investigate compliance with action plans 
and thereby decrease asthma events.  
 
 
2.4.6 Health and well-being ”apps”  and issues of evaluation 
     There are now myriad online smartphone applications for health and well-being that can 
be readily downloaded online. These applications (commonly called “apps”) are provisioned 
by various sources including manufacturers, service providers and independent software 




developers. They are typically simple providers or collectors of information and can often 
lack any formal evaluation. To distinguish these tools from the more formally documented 
application technology documented in the literature, I refer to these as apps rather than 
applications. Of course, not all freely downloadable apps are unevaluated. Medscape (2014) 
for example, is a mature, professional clinical web resource that is well documented in the 
literature and, for which, an app can be freely downloaded. Similarly, there are professional 
NICE (National Institute for Health and Care Excellence) guidance apps: NICE BNF (2013) 
and NICE guidance (2013). However, the majority of health-related apps do not provide any 
information about the involvement of users in their design nor about any evaluation, and only 
a few have provided evidence of effectiveness and user acceptance (Sarasohn-Kahn, 2010). 
Naturally there is concern regarding the content of these apps and a concern regarding a lack 
of regulation for the technology (Rosser and Eccleston, 2011).  
    
   Huckvale et al. (2012) have observed there is no conclusive evidence that mobile apps for 
asthma self-management are better than existing document-based methods and that most of 
the mobile apps available for asthma self-management are not able to combine reliable and 
detailed information; many of them providing inadequate or imprecise information and some 
providing unsafe tools. Similarly, Chomutare et al. (2011) revealed that despite the enormous 
growth in apps for diabetes self-management, evidence of the effectiveness of these 
applications is limited; education features are missing in most of them; and evidence-based 
recommendations are commonly overlooked. Likewise, Rosser and Eccleston (2011) in a 
review of pain management apps (typically providing information and supporting diary 
tracking) noted a lack of clinical involvement in their design and in the creation of their 
content; they also observed that the majority of reviewed apps claim to provide pain relief, but 
their effectiveness has not been evaluated, nor have their secondary effects been assessed; the 
authors conclude that there is a risk of individuals being misled. Also Visser, Korevaar & 
Nolan (2013) have pointed out that since mobile applications for healthcare are freely 
available, there is a lack of control in their use, and they can contain unreliable, out-of-date or 
misleading information. The authors foresee a need for "certification of approval" so that 
clinicians and users could determine if app designs have involved medical expertise and if 
they provide accurate information, are clinically safe and free from bias, and have been 
developed and evaluated according to regulated practices. But, of course, this vision is 
enormously challenging: potentially eradicating healthcare apps by inflicting the full burden, 
expense and delay of clinical trial evidence on to the app developers and researchers who 




could probably never support the expense nor, perhaps, could their solutions survive the delay 
without a risk of obsolescence. 
 
2.5 Pervasive healthcare research in anaphylaxis management 
     Despite the potential of pervasive healthcare and the breath of applications reported in the 
literature, there is comparative neglect for allergy and, in particular, for anaphylaxis (Vavoula 
& Lonsdale, 2007), a condition which has increased worldwide to near epidemic prevalence 
(Simons and Sampson, 2008). 
      Some of the few pervasive health applications for allergy found in the literature are early 
evaluations of functional prototypes such as the Smart Food (Gassner et al., 2005) and the 
ScanAvert (Badinelli, 2006) applications, which were personalised PDA applications designed 
to read product barcodes. The aim being that allergy sufferers could check ingredients for their 
allergens. Unfortunately, these solutions did not overcome the challenges of connecting to 
reliable and updated product databases which would have required cooperation between food 
manufacturers and retailers. Another research effort, similar to reading barcodes, was 
presented by Jara et al. (2010). It was a mobile phone system designed to avoid adverse drug 
effects on patients by checking for allergens in their electronic health record. Although this 
research demonstrated the feasibility of such a system, its usability, user acceptance and health 
effectiveness were not reported. 
 
2.5.1 Smartphone “apps” for anaphylaxis management 
     Recently, a number of smartphone apps have been created to support anaphylaxis 
management. A search of the Android (Google Play) and the Apple (App store) stores with the 
word "anaphylaxis" returned nine such apps; none of which have reported evidence of their 
evaluation in the literature. They are summarised in Table 2.1.  
     All the smartphone apps for anaphylaxis management shown in table 2.1 provide 
information in English. Six applications are free and three require a download fee. Most of 
them have been developed by healthcare or anaphylaxis organisations: Anaphylaxis (2013) 
was developed by a UK university with support from the Anaphylaxis Campaign UK. Two 
apps (Jext UK, 2013 and Auvi-Q, 2013) were developed by AAI manufacturers. React! (2013) 
was developed by an NHS hospital in Newcastle, UK. WhyRiskIt? (2013) was developed by a 
Canadian anaphylaxis organisation and the remaining three apps (Anaphylaxis 101, 
Anaphylactic shock, AllergySense and alert5) were developed by independent companies.  


















(i.e., it does not 






-Contains emergency procedure information 
(including video). 
-Users can press a button to dial 999. 
-Saves emergency contacts. 
-Supports AAI reminders. 
-Can locate nearest hospital. 
-Clinically informed design and developed in 
collaboration with the Anaphylaxis Campaign UK. 
-Supports different AAIs. 




Abello Ltd, 2013) 
 
Free 








-Can save a personal profile. 
-Shows step-by-step instructions to use Jext AAI. 
-Supports one Jext AAI expiry alert. 
- Contains audio instructions to use the Jext AAI. 
-Customised for Jext AAI. 
 
React ! (Great 
North Children’s 
Hospital, Newcastle 
upon Tyne, 2013) 
 
Free 
Not reported Not reported 
-Designed for teenagers. 
-Based on emergency simulated scenarios. 
-Contains video-animation about adrenaline 
injection steps. 
-Supports different AAIs. 
-Clinically informed design. 
 
-It is a web application, not 
available for download 




















-Contains audio step-by-step instructions for the 
Auvi-Q AAI. 
-Can dial to 911 and notify contacts using text 
messages. 
-Can store a personal profile. 
-Provides AAI expiration and training reminders. 



















-Comprises facts on food allergies and anaphylaxis. 
Information on allergies, common causes, signs & 
symptoms and treatment. 
-It is linked to the “Why Risk It?” Blog (stories, 
articles and tips written by teenagers and young 
adults with food allergies). 
-Only provides information 
about anaphylaxis but there 
is not any other type of 












-Contains a short educational video about 
anaphylaxis. 
-Only available for 
Android devices. 








Not reported 10-50 (Android) 
-Shows information about first aid response 
(animation) to allergic reactions. 
-Only available for 
Android devices. 













-Provides AAI expiry date reminders. 
-Contains allergen tables and ingredient substitutes. 
-Provides food recipes. 
-Focused on food allergies 
more than anaphylaxis. 








(standard version is 
free) 
 







-The standard version sends text messages to five 
emergency contacts with the user’s GPS location 
and supports dial to emergency services. 
-The anaphylaxis version provides standard version 
functionalities and shows on screen personal health 
data and a note to ask for assistance.  
-This version was developed in collaboration with 
“what allergy?” blog (food allergies eczema and 
asthma.) 
-Apart from emergency 
messages and GPS 
location, it does not 
provide any other type of 
support for anaphylaxis 
management. 
-The anaphylaxis version is 
not free. 




      
   Anaphylaxis (2013) was developed with medical input; it provides tools to save personal 
information about allergies, medications and emergency contacts. It supports emergency 
reminders for different AAI manufacturers. For emergency situations, it contains information 
about anaphylactic symptoms and emergency procedures; supports 999 dialling and provides 
information about medical services nearby. React! (2013) was designed to be viewed in a web 
browser and is not available as an app for download. It was aimed at educating teenagers in 
anaphylaxis management through simulated video scenarios and contains information on the 
use of different AAIs. It can also save a personal profile with information about allergies and 
the type of injector used. Jext UK (2013) supports the creation of personal profiles that can be 
emailed to other people. It uses text and video to show the steps required to inject adrenaline 
using their own Jext AAI. It can provide expiration reminders for one Jext AAI and offers 
audio and step-by-step instructions for that injector.  Similarly, Auvi-Q (2013) is a customised 
application that supports the use of its Auvi-Q AAI with audio instructions. For emergencies, 
it offers 911 dialling and text messaging to emergency contacts. It can also provide AAI 
expiration and training reminders and can store a personal profile. However, it does not 
support other AAIs, nor does it provide information about anaphylaxis management. 
WhyRisKit? (2013) provides only information about food allergies and anaphylaxis, 
Anaphylaxis101 (2012) contains only a short educational video about anaphylaxis, 
Anaphylactic shock (2011) is limited to an animation with first aid instructions and 
AllergySense (2013) provides food recipes and ingredients substitutes and AAI expiry date 
reminders. alert5 (2014) is a free application that supports text messages with GPS location to 
five emergency contacts, but it has an anaphylaxis version that is not free but extends on the 
standard version with emergency service dialling and on-screen information with personal 
health data and a note to ask for assistance. 
 
     In general, apps stores report good levels of popularity for anaphylaxis apps (as stars), but 
the number of reviews is very low and the numbers of downloads are imprecise or not 
reported. For example, Auvi-Q (2013) appears to be the most popular anaphylaxis app at the 
time of writing, ranging from 1000-5000 downloads and 4.5 stars (out of 5) in the Apple store 
and 3.3 stars (out of 5) in the Android store, but it has had only a limited number of reviews 
(13 and 16 reviews, respectively). The number of downloads for Jext UK (2013), WhyRisKit? 
(2013) and Anaphylaxis 101 (2013) ranged from 100 to 500, but they had only a very few 




reviews. While, the number of reviews and the number of downloads of Anaphylaxis (2010) 
and AllergySense (2013) apps have been reported as too low to display in the Apple store. 
 
     In summary, although most of the anaphylaxis smartphone apps appear to have been 
informed by expert input from anaphylaxis organisations or AAI manufacturers, there is, as 





    Self-efficacy refers to the “beliefs in one’s capabilities to organize and execute the courses 
of action required to produce given levels of attainments” (Bandura, 1998:624). Self-efficacy 
theory establishes an association between people’s belief’s and behavioural change, and  
hypothesises that expectations of personal self-efficacy determine if a specific behaviour will 
begin, the amount of effort that will be invested in the behaviour and the length of the 
behaviour in the presence of obstacles and challenging experiences (Bandura, 1977). The 
theory was developed by Albert Bandura, a famous psychologist and long-term Stanford 
professor. He is the fourth most-cited psychologist of all time and the most cited living 
psychologist (Haggbloom et al., 2002). He is known for the theoretical construct of self-
efficacy and for the development of social cognitive theory, subjects about which, in his 
eighties, he continues to write.  
 
2.6.1 Self-efficacy sources of information 
 
Self-efficacy is defined as having four sources of information (Bandura, 1977):  
 
1) Enactive experience (performance accomplishments) is a source of self-efficacy 
grounded on personal mastery experience. Mastery expectations are enhanced by repeated 
success and they are the most effective way to acquire higher levels of self-efficacy (Bandura, 
1998). Performance accomplishment can cause significantly more changes in behaviour (in 
less time) than any other source of self-efficacy. Occasional failures do not diminish self-
efficacy when persistent effort helps overcome difficulties (Bandura, 1977). Persistence, 
through mastery, minimises defensive behaviours and improves self-efficacy which can then 
generalise to other activities, for example, Bandura (1977) found that overcoming phobias to 




specific animals can improve efforts in social situations, decrease worries about other animals, 
and improve levels of anxiety and stress.  
 
2) Vicarious experience also known as modelling enhances self-efficacy through observing 
other people performing challenging activities with success (Bandura, 1977). This can 
enhance the expectations of the observer and ‘persuade’ them that they can do it ibid. In 
particular, observing models, who required great determination and persistence, can enhance 
the self-efficacy perception of the observer ibid.  
 
3) Social persuasion or verbal persuasion can increase levels of self-efficacy when, for 
example, people say something encouraging (e.g., “you can do it”) in order to motivate a 
behavioural change, though this type of intervention may be weak if past or negative 
experiences are present (Bandura, 1977). Vicarious experiences and social persuasion can 
modify levels of self-efficacy independently of enactive experiences (Bandura, 2012) 
 
4) Physiological states such as stress or emotional arousal can be perceived by some people 
in some circumstances as indicators of personal competency, but in others, a state of alert to a 
threatening situation (Bandura, 1977). High emotional arousal or stress levels may diminish 
self-efficacy, performance and success, but it can be decreased by vicarious and mastery 
experiences (Bandura, 1969).  
 
2.6.2 Rationale for incorporating self-efficacy theory in the management of chronic 
diseases 
 
     The main reason for using self-efficacy theory in the management of chronic diseases is     
that research in healthcare (as well as research in academic achievement and psychology) has 
shown that self-efficacy beliefs are contributors of performance, are strong predictors of 
behaviour and are major determinants of action (Bandura, 2012). And action is required in the 
management of chronic medical conditions (Bandura, 1998). The influence of self-efficacy in 
human health is twofold: first, self-efficacy beliefs regarding one’s capacity to handle stressors 
affects the regulation of the immune system (Bandura, 2012). The higher the self-efficacy, the 
higher the capacity to manage the biochemical reactions caused by stress hormones and the 
higher the performance of the individual. Second, self-efficacy beliefs help manage health 
behaviours. They determine habit change, motivation and perseverance toward success, as 




well as maintenance, susceptibility to decline and success in recovering from challenges 
(Bandura, 2012). It is important to note, though, that self-efficacy is different from self-
esteem. Self-efficacy is a judgment of capability, while the latter is a judgment of self-worth 
(Bandura, 2012). Self-esteem has no significant effect on self-efficacy (Bandura, 1997). 
 
   Barlow et al. (2001) reports self-management as referring "to the individual's ability to 
manage symptoms, treatment, physical, psychosocial consequences and life style changes 
inherent in living with a chronic condition", with the aim of maintaining an acceptable quality 
of life, and establishing a permanent process of self-regulation. The self-management 
approach can be a generic model that can be adapted to different chronic conditions and can 
further increase health benefits through mastery mechanisms of self-efficacy (Bandura, 1998). 
For example, in the context of self-management, mastery skills could be improved through 
action; vicarious experience could be provided by written instructions, photos, actors, trained 
peers, health professionals or videos to model health management tasks. While carers, support 
groups, psychologists and medical specialists could provide encouraging feedback that can 
enhance the social experience and improve physiological states (Lorig & Holman, 2003). 
 
     In the context of health self-management, self-efficacy increases adoption and maintenance 
of health habits (Bandura , 1997). These habits include the management of treatment (e.g., 
drug adherence) and symptoms, psychological consequences, lifestyle (e.g., exercise, 
nutrition, diet or smoking), social support, communication with doctors and decision making 
(Barlow et al., 2002).  
 
     It has been found that self-management programmes based on self-efficacy theory can 
improve health status while reducing hospitalisations of people with diabetes, arthritis, asthma, 
stroke, lung disease and heart disease (Lorig et al., 2001). For example, self-management 
programmes for diabetes types I and II have shown that self-management education correlates 
with improved glucose levels (Norris et al., 2002), treatment acceptance and maintenance of 
correct glucose levels (Gregg, 2007), and weight loss and smoking cessation (Davies et al., 
2008). 
 
     Lorig & Holman (2003) report that self-management education for arthritis management 
grounded in self-efficacy theory can offer significant and continuous benefits to patients at a 
lower cost than traditional carer education programmes. The benefits include improved patient 




behaviours, for example, an increase in the number of minutes per week of exercise and in 
symptom management techniques such as relaxation and communication with physicians.  
 
     Despite the benefits demonstrated by self-management programmes based on self-efficacy 
theory, little has been applied to studies for anaphylaxis management. One of the few 
exceptions was a study carried out by Litarowsky, Murphy & Canham (2004), who designed 
a training program for high school staff. The program utilised experiences of mastery, social 
persuasion and vicarious experiences to train 53 people in recognising anaphylaxis and using 
AAIs. The programme used slide presentations, videos, AAI “face to face” demonstrations, 
AAI “hands-on” practice and verbal feedback. Symptom recognition and adrenaline injection 
knowledge and self-efficacy were measured before and after the training. The study authors 
reported significant improvements in knowledge and self-efficacy, but noted the absence of a 
control group. It is worth noting that, at the time of the study, Bandura’s (2006) 
recommendations on self-efficacy questionnaires had not been published and there was no 
other self-efficacy questionnaire for anaphylaxis management in the literature. Thus, the 
study authors created a questionnaire with a response scale ranged from 1 to 4. Bandura 
(2006) recommended a more sensitive scale from 0 (i.e., cannot do) to 10 (i.e., highly certain 
can do). The study was later replicated by Lee (2011) but using the same questionnaire. 
 
2.6.3 Self-efficacy in pervasive healthcare research studies with mobile devices 
 
     There have been studies in pervasive healthcare research with mobile devices that have 
evaluated self-efficacy levels, but only a few of them have been grounded in self-efficacy 
theory (Free et al., 2013).  
 
    For example, in a three-month phase one randomised control trial, Faridi et al. (2008) 
assessed the use of mobile phones on type II diabetes self-care. The intervention group (15 
participants) received daily tailored text messages to improve their diabetes self-care while the 
control group continued with their usual self-management program. Non-significant 
improvements in glucose levels were found in the intervention group and non-significant 
deterioration in the control group. However, self-efficacy levels (measured with a diabetes 
self-efficacy scale) improved significantly in the technology group. Likewise, Haapala et al. 
(2009) investigated whether a one-year controlled randomised text messaging program could 
improve weight loss. The intervention included customised text messages to 62 overweight 




adults that reported their weight daily and received immediate feedback. The authors reported 
that the technology group had significantly higher weight loss and higher waist circumference 
diminution. They also identified that self-efficacy in dieting (quantified with a questionnaire), 
attitudes towards the technology and work and family life were strong predictors of weight 
loss. Similarly, Fukuoka at al. (2010) piloted a mobile phone intervention to assess the 
potential to motivate 41 sedentary women to increase their physical activity. Pedometer step 
count was used as input to the mobile phone application which provided immediate and daily 
feedback, and motivational messages and prompts highlighting benefits of exercise. The study 
lasted three weeks. There was no control group. The self-efficacy for physical activity survey 
(SEPA) was used to quantify the degree of confidence that participants had in doing physical 
activity. Results showed that participants were motivated to carry out physical activity and the 
daily amount of steps and average caloric expenditure improved. However, self-efficacy levels 
were similar before and after the study. The authors suggested this was likely due to the short 
term nature of the intervention. 
 
     In a review, Krishna, Boren & Balas (2009) evaluated 25 clinical controlled studies 
involving text messages and mobile phone voice interventions in healthcare applications 
including diabetes, HIV, asthma, anxiety and smoking cessation. The authors concluded that 
standard care supplemented with text message reminders, disease monitoring and mobile 
phone voice interventions can help improve patient self-efficacy and outcomes such as 
behaviour modification, medication compliance, medication adherence, symptom 
improvements and quality of life and also can help improve processes of care such as 
communication with patients and appointment attendance.  
 
     Examples of studies grounded on self-efficacy theory are less common. For instance, in a 
review of 26 controlled trials of mobile devices for healthcare that implemented behavioural 
change or disease management interventions, Free et al. (2013) identified only four studies 
based on self-efficacy theory and only three more based on other theories of behavioural 
change. The four studies grounded in self-efficacy theory involved interventions for type II 
diabetes education, smoking cessation for people living with HIV/AIDS, exercise intention 
enhancement with text messages and text messages for monitoring physical activity. The 
authors concluded that behavioural change interventions with text messages that encourage 
smoking cessation and antiretroviral medication adherence are effective and their 
implementation should be considered for inclusion in clinical services. 





     Finally, in a recent University of Utah Ph. D. thesis on the infusion of self-efficacy theory 
in a walking encouragement application, Koyle (2013) used SMS text messages to investigate 
whether this technology may encourage walking for exercise and affect levels of walking and 
self-efficacy. The author found that a mobile application may have potential to promote 
walking and changes in walking self-efficacy in the short term. However, the work did not 
involve participatory design and provided little information about how the components of self-
efficacy were implemented in the mobile application and in the text messages and there is no 
report of benefits in outcome measures such as weight loss or body mass index. 
 
2.7 Summary of this chapter 
     Chapter one looked at anaphylaxis management and how day-to-day management of 
anaphylaxis involves allergen avoidance and being prepared for an emergency. It considered 
the unmet needs, in particular, needs regarding adrenaline injection training. This chapter has 
shown that pervasive healthcare research with mobile devices provides opportunities to 
support people with chronic diseases and also to support self-management. The chapter also 
reported a lack of solutions grounded in self-efficacy theory despite the benefits of 
incorporating it into the design of pervasive healthcare solutions.  
 
                               











     This chapter presents the results of early multi-stage proof-of-concept prototyping that 
helped to understand how anaphylaxis management needs and people’s preferences might 
translate into usable and beneficial tools to supplement traditional care documents. As shown 
in the literature review, pervasive healthcare technology has the potential to support chronic 
disease management, but little research has been done for its application to anaphylaxis. The 
laboratory prototyping work described here evolves from a first study exploring technological 
possibilities through to a study with a functional smartphone prototype design with support 
for adrenaline injection training. 
 
     As a new application of technology to anaphylaxis management, the research involved here 
was aimed at producing pre-clinical testing results that might usefully inform phase one 
testing. Of specific interest was an appreciation of the usability issues relating to the use of this 
technology. Though, of course, the aim was not to supplant the traditional system of 
anaphylaxis management (i.e., the advice, training and documentation provided to anaphylactic 
people), but rather to supplement it. For example, it was not anticipated that a mobile phone 
solution would replace the in-person clinical advice and training that forms the basis of the 
traditional system of care, but rather that it would supplement the traditional document-based 
support. 
                               




    The “multi-stage prototyping” methodology proposed by Matthews et al. (2008) 
recommends a three-stage evaluation: focus group, peer study and clinical evaluation. This 
chapter presents results from the first two stages, focus group and peer study evaluation 
through three studies. The methods used in each study are as follows: 
 
     Study one involved direct observation and questionnaire feedback regarding user needs 
and preferences from 19 families attending anaphylaxis training workshops organised by the 
Anaphylaxis Campaign UK. The aim of the study was to investigate technological 
possibilities. The needs analysis (Smith, 2011) informed the design of a first laboratory 
keypad smartphone and wireless injection-sensing AAI prototype, PervaLaxis 1 (from 
Pervasive anaphyLaxis), and a formative usability evaluation performed with a small number 
of anaphylactic and non-anaphylactic people.  
 
     Study two was designed to evaluate the usability of an improved prototype, PervaLaxis 2, 
implemented in a touchscreen smartphone with an improved interface informed by feedback 
from study one. The study was carried out with a group of 32 non-anaphylactic participants 
using traditional care paper documents and PervaLaxis 2 smartphone materials. The purpose 
was to continue assessing formative usability and begin to investigate measures of summative 
usability (effectiveness, efficiency and satisfaction). Questionnaires of self-reported workload 
and usability were used in the assessment of different tasks. A thematic analysis of debrief 
interviews was also carried out to investigate aspects of usability and identify advantages and 
disadvantages of traditional care paper-documents materials vs the smartphone tools. 
 
     Study three was designed as 'early research' (phase zero) investigative pilot testing as per 
clinical trial methodology (NHS, 2013). The PervaLaxis 3 prototype used in this study 
comprised the same phone and wireless sensing hardware and software as PervaLaxis 2, but 
incorporated video animation tools (recommended in study two evaluation). A two-arm, 
laboratory, randomised controlled study with groups of 11 non-anaphylactic participants was 
undertaken to investigate the benefits on adrenaline injection training. One group used 
traditional care paper documents (control group) and the other group (the intervention group) 
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used the tools implemented in the PervaLaxis 3 prototype. Participant injection performance 




3.3 Anaphylaxis management scenarios 
     The work underpinning the studies required consideration of the people involved in 
anaphylaxis management and possible scenarios of use to illustrate the context of the 
activities, as recommended in the Human-Centred Design standard (ISO 9241-210, 2010). 
Based on the clinical literature
2
, effective management of anaphylaxis requires cooperation 
between the anaphylactic person, health providers and supporting people, for example, from 
carers, family and friends.  
 The anaphylactic person (depending on age and capacity) is responsible for management 
tasks such as managing medication and diet, avoiding allergens, attending medical 
appointments, having an emergency "Allergy Action Plan" (a plan that provides a 
summary of symptoms, emergency actions including AAI use, allergy details and 
emergency contacts) (BSACI, 2014) and educating and training others about AAI use and 
emergency procedures (NICE, 2011; Simons et al., 2011). 
 Health providers are the practitioners or specialists responsible for diagnosing, 
establishing treatment, maintaining records, providing advice and encouraging self-
management. (Resuscitation Council UK, 2008; Carlisle et al., 2010). 
 Supporting people may be carers, trained supporters and untrained supporters. Their level 
of responsibility may vary. For example: 
o Carers such as family members or close friends are more likely to be trained to 
support emergency and everyday life activities and to have some responsibility for 
care and anaphylaxis expertise (RCPCH, 2011). Helping, for example, with 
avoiding allergens, managing medications, following an emergency Allergy 
Action Plan and, where appropriate, encouraging independence (Simons, 2006).  
o Trained supporters such as health providers, school nurses and teachers, first 
                                                          
1
 The number of participants having a smartphone increased over the time of the studies as follows: Focus group (2008): 21.1 
%, Study one (2009): 25% , Study two (2010): 21.1 %; Study three (2012): 86%. This mirrors levels of smartphone 
penetration in the USA in those years, though globally the increase has been somewhat slower (Statista, 2014).  
 
2 The websites consulted to search for clinical literature on anaphylaxis management were: Web of knowledge/Web of 
Science, PubMed and Google Scholar. And the search term were: “anaphylaxis management” and "anaphylaxis", 
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aiders, friends and co-workers, are examples of the people who would be familiar 
with the emergency Allergy Action Plan and trained to support the person in an 
emergency, for example, trained in adrenaline injection (Kemp, Lockey & Simons, 
2008).  
o Untrained supporters, such as classmates or colleagues, may be familiar with the 
person’s anaphylactic condition but not explicitly trained (Simons, 2006). These 
people may be in attendance in an emergency and might, for example, recognise a 
possible reaction event and understand the need to summon help quickly (RCPCH, 
2011).  
 
     From anaphylaxis guidelines (National Institute of Allergy and Infectious Diseases, USA, 
2010; NICE, 2011; Resuscitation Council UK, 2008; Simons et al., 2011) and the relevant 
medical literature (Lieberman et al., 2010; RCPCH, 2011; Wang, 2010) two main types of 
scenarios regarding anaphylaxis management in the community can be proposed: emergency 
scenarios and everyday life scenarios. 
 
     Emergency scenarios may result from touch, inhalation or ingestion of an allergen. 
Reactions can occur anywhere: at home, in restaurants, at school or on vacation, at the homes 
of relatives and friends, children’s nurseries, hospitals or clinics (NICE, 2011) (Clark and 
Ewan, 2008). People with anaphylaxis should follow their Allergy Action Plan (BSACI, 
2013) and, after detecting anaphylactic symptoms, should inject adrenaline and an ambulance 
should be called (Pumphrey 2004). The allergen should, where possible be identified, contact 
removed and other triggers like exercise should be avoided (RCPCH, 2011). If there is no 
improvement in 5 to 10 minutes, a second injection should be given (The Anaphylaxis 
Campaign UK, 2010). The patient should lie flat with their legs raised (Pumphrey, 2004). 
Antihistamines and steroids are the second line of treatment (Resuscitation council UK, 
2008). After suffering an anaphylactic event the patient should be transferred to an emergency 
department for observation and, as appropriate, carers contacted (Simons et al., 2011). 
     Everyday life scenarios in the management of anaphylaxis involve a range of activities 
requiring training and continuous practice (Kemp, Lockey & Simons, 2008). For example, 
anaphylactic people need to avoid allergens (Simons, 2009) and check product labels and 
ingredients (Walker & Sheikh, 2003). They should carry AAIs and know how to use them 
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(Simons et al., 2011). The AAIs should be in-date (not expired) and always at hand (Walker et 
al., 2010; Baral & Hourihane, 2007). Patients and carers should know how to recognise 
anaphylactic symptoms (RCPCH, 2011; Resuscitation council UK, 2008) and have an 
emergency Allergy Action Plan outlining the correct emergency procedure (Lieberman et al., 
2010; Sicherer et al., 2010; Simons, 2010; Simons et al., 2011). They also need to manage 
risks (RCPCH, 2011), maintain a nutritious diet (Carlisle et al, 2010), attend medical 
appointments (NICE, 2011), have ready access to information about allergies and, ideally, 
wear medical ID such as a medic alert bracelet (Sicherer et al., 2010; Simons, 2010). 
Importantly, people with anaphylaxis need to interact with others, (supporting people and 
carers), explaining about their allergies and training them as appropriate, for example, about 
their Allergy Action Plan and in the use of AAIs (Kemp, Lockey & Simons on behalf of the 
WAO, 2008).  
 
3.4 Study One – PervaLaxis 1  
3.4.1 User needs and preferences 
 
     The task of gathering the user needs that led to tools implemented in PervaLaxis 1 
involved observations and discussions with 19 anaphylactic children and young adults (from 8 
to 25 years old) and 21 parents/carers in two training workshops organised by the 
Anaphylaxis Campaign UK. In addition to observations and discussions during the 
workshops, questionnaire feedback was obtained. The purpose of the questionnaire was to 
investigate users’ needs and preferences, for example it asked about their allergic reactions, 
the number (and manufacturer) of AAIs carried, their familiarity with and usage of 
smartphones, and their suggestions for support in everyday life and emergency scenarios. 
Nineteen questionnaires were returned (one per family). 
 
     Questionnaire feedback indicated that at the time of the workshops (2008) only four 
families had used a smartphone or a PDA (21%). In that year the usage of smartphone devices 
was not as high as at the time of writing this thesis (in 2008 the global smartphone penetration 
was 12% (Statistica, 2014)). Most of the anaphylactic people that attended the workshops 
carried two Epipen® AAIs (69% - 13 families), or one Epipen® AAI (21% - 4 families) and 
only two families mentioned having more than two Epipen® AAIs (10.5 %). Nobody had an 
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Anapen® AAI or any other manufacturer’s AAI. Respondents typically carried two AAI and 
a mobile phone. Their parents, or family and friends often also carried a mobile phone 
specifically for contact in emergencies and they also sometimes carried spare AAIs.  
Regarding the use of pervasive healthcare technology, questionnaire results indicated that 
only eight families (42%) were interested in receiving SMS food alerts (warnings about 
wrongly labelled foods in the supply chain). Nevertheless, most of them, 14 families (73.7%) 
were interested in receiving alerts when an AAI was opened or used. 
 
     The workshops were guided by trained instructors of the Anaphylaxis Campaign UK. The 
first workshop was a short two-hour training session attended by five families. The second 
workshop was a full day training workshop for families with teenage children. Fourteen 
families attended. This workshop involved broad coverage of self-management activities and 
also “risky situation” role play opportunities for the teenagers. The researcher was allowed an 
ethnographic opportunity as a workshop assistant and group leader; helping, observing and 
note-taking for the teenage activities, and was also provided with 20 minutes to discuss ideas 
with attendees about how technology could support anaphylaxis management.  
     
     The suggestions proposed in discussion and in questionnaire feedback about technological 
implementations that they wanted included: an emergency alarm to call an ambulance and 
contact/message family, a tool to help with AAI use and to manage AAI expiry dates, 
educational videos about anaphylaxis, food alerts and also a variety of other suggestions 
including a tool to detect nearby AAIs, to automatically detect AAI opening or use, and 
messages in different languages for travel abroad. In general, parents of pre-teen children 
wanted control over emergency settings and information, whereas parents of teenagers wanted 
less control and instead wanted to resource the children to take control of their allergies. 
Nevertheless, it was observed that people had difficulties imagining how new technology 
could support their anaphylaxis management needs, perhaps because only a few of them had 
experience with smartphones and perhaps because they were still learning about anaphylaxis 
management at that time. These reasons also precluded the use of participatory design which 
requires user understanding of the subject domain (Muller, 1991). 
 
 
                               
























Fig. 3.1 PervaLaxis 1: (L-R) Main screen; AAIs expiry date list screen; injection detection 
and emergency text messaging support. 
 
 
     Fig. 3.1 shows screenshots from PervaLaxis 1 and a schematic of the emergency text idea. 
Table 3.1 summarises the tools implemented. They included the more popular suggestions of 
the workshop participants such as the AAI expiry date list, AAI training support (a tool for 
sensing injection “jab” motions), educational videos, an emergency text message and a list of 
emergency contacts (who would receive automatic text messages in an emergency). In 
addition, an emergency location tool was implemented to explore if text messages could have 
more meaningful location names rather than just GPS locations, for example, “Mary has used 
an Auto-Injector at school” or “John has opened an Auto-Injector at Grandma’s house”. The 
technical objectives of this prototype were fairly ambitious, for example, attempting to 
automate injection detection was computationally demanding (given excessive false positives 
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would need to be avoided) and also very demanding over the long-term in terms of power 
consumption.  
 
Table 3.1 Functions implemented in PervaLaxis 1. 
Scenario 
User  





Help injecting adrenaline 
Injector trainer 
 
This fucntion informed 
users if they have injected 






adrenaline expiry dates 
Injectors expiry date list 
 
It kept a list of expiry dates 
and reminders to replace 
AAI them before they 











It contained a video 






Detects injections and 
sends messages to 
emergency services and 
carers 
Adrenaline injector status 
Emergency alarm 
 
After detecting a possible 
injection of adrenaline, it 
sent SMS messages to 







Emergency messages to 




It allowed the creation of 
personal locations based on 
GPS coordinates to be 







Maintain a list of contacts 
Parents emergency 
settings   
Contact list 
 
It helped manage a 
personalised list of 
important people to inform 
in case of emergency. 
 
 
3.4.2 PervaLaxis 1 hardware (created in 2009) 
 
     The PervaLaxis 1 hardware and Windows 5.0 keypad smartphone (v1240, 200 MHz 
HTC-Vodafone) are shown in Fig. 3.2 The PervaLaxis 1 application was created using Visual 
Studio 2005, C#. The smartphone received wireless data from a three-axis accelerometer 
mounted on an Epipen© AAI trainer and also from an external GPS module (GPS-BN90 
BlüeNext). It was not clear at this early stage of technology exploration whether this sensor 
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could be for mounting on real (adrenaline-filled) AAIs as well as trainers, but for the purposes 
of testing the injector needed to be a trainer. The rather ambitious idea was that sensed 
information could be used to detect possible emergencies and respond, for example, with 
generating SMS messages to carers and emergency services. Emergency messaging services 
that support mobile phone SMS communication have emerged in recent years, for example, 
there is Emergency-SMS in the UK allowing deaf and speech-impaired people, to register 
mobile phones from which they can send SMS messages to emergency services 
(www.emergencysms.org.uk, 2012). A text-to-911 service in the USA was introduced in 2014 
and now has “limited availability” (www.fcc.gov/text-to-911, 2014).  
 
 
Fig. 3.2 PervaLaxis 1 components: a) GPS module; b) Smartphone device;  c) AAI trainer 




     User interface inspection,  System Usability Scale (SUS) (Brooke, 2006) and NASA TLX 
(NASA, 2003) questionnaires were used for evaluation. The SUS questionnaire was used to 
provide a measure of perceived usability, covering aspects of acceptance, need for support, 
training and system complexity (Jones & Marsden, 2006; Preece, Rogers & Sharp, 2002). 
NASA TLX questionnaires were used to quantify levels of mental, physical and temporal 
demands, and self-reported levels of performance, effort and frustration. Each scale has 21 
vertical marks that divide it from 0 to 100 in increments of 5. Low demand levels could 
indicate that a task would be more likely to be successful in a real scenario (Brewster et al., 
2003). Eight participants were involved in the evaluation. Two participants were anaphylactic 
people already trained in anaphylaxis management, an eight year old child (who used the 
system with his mother) and a twenty-one year old nurse. The remaining six people were 
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adults between 27 and 40 years old, three with knowledge of allergy and anaphylaxis and 
three without. After signing consent forms and agreeing to participate, they were first 
introduced to traditional care paper-documents provided by the anaphylaxis campaign and an 
AAI manufacturer and then shown PervaLaxis 1. Later, they carried out six tasks 
(Summarised in table 3.2) to inspect and use the implemented tools: familiarisation with the 
user interface, adrenaline injection training, emergency messaging, using information tools 
with videos, managing injector expiry dates and creating locations for text messages. 
Questions and communication with the researcher were allowed. Additionally, in a debrief 






Table 3.2 Tasks undertaken in the usability evaluation of PervaLaxis 2. 
Task 1 
User interface 
Participants were asked to familiarise themselves with the smartphone user interface and 




Participants opened the AAI trainer tool and perform several injection attempts in different 





Participants were asked to keep PervaLaxis 1 in the main window, make an injection with 




Participants were asked to open the information tool and play a video (produced by the 




Participants were asked to open the AAI expiry date tool, add a new expiry date to the list, 








                               




      
System Usability Scale (SUS) results. To make a comparison between the traditional care 
paper-documents (provided at the beginning of the evaluation) and PervaLaxis 1, SUS 
questionnaires (Brooke, 2006) were completed for both. Participants reported that PervaLaxis 
1 was easier to use and more user-friendly. However, participants considered that the use of 
this new technology needed extra support, at least at the beginning of its use to become 
familiar with the smartphone interface. They felt that there was little difference in the time 
spent learning how to use the new system compared with reading traditional sources of 
information. They reported that PervaLaxis 1 was more consistent and more integrated 
because they did not have to spend time looking for information in several places nor carry 
paper everywhere. They also expressed an increased confidence in their ability to manage an 
emergency situation with PervaLaxis 1. The SUS score for the traditional paper-based method 
was 50.3, while for PervaLaxis 1 it was 79.6, suggesting that PervaLaxis had improved 
usability. According to Bangor, Kortum & Miller (2008:592) this translates to between poor 
and ok usability for the traditional paper-based method, and good to excellent for PervaLaxis 
1. 
 
     NASA TLX results. After completing each task participants completed a NASA TLX 
questionnaire about their perception of the implemented functionality. It can be seen in Fig 
3.3 that the initial use of the smartphone interface was demanding with participants reporting 
the highest effort and the highest frustration for this task. This may have been because 
participants either felt unfamiliar with the Windows Mobile 5.0 smartphone or because it was 
difficult to use. The injection training tool was reported as physically demanding. It required 
participants to practice injections (pushing and pulling the AAI on the outer thigh). Despite 
this, participants reported a degree of satisfaction about performing the injection correctly and 
about the potential the tool could have to help train others. "SetUp emergency scenario" was a 
task that participants perceived as easy, injections were recognised and SMS text messages 
were sent. Participants liked this feature but wanted explicit and clear confirmation about the 
messages so that they could be confident these were sent. Low TLX scores for the videos tool 
agreed with participant reports that this tool was easy to use and that the video was more 
useful than reading the equivalent information on the instruction leaflet, however, some 
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participants mentioned that the screen was small. The injector expiry date list also had a fairly 
low TLX score. One of the anaphylactic participants reported that this tool could be especially 
useful since they had forgotten several times to replace expired AAIs. Creating locations had 
a high TLX score. It had the highest mental demand, the lowest self-reported performance and 
a high level of frustration. Creating location names was a more advanced feature of 
PervaLaxis 1 requiring more navigation and more key presses, and it proved the most 
polemic, separating the users into those who found it easy and useful and those who found it 
difficult to understand and difficult to implement. Here, the need to navigate menus, look and 
















Fig. 3.3 NASA TLX results.  
   
     Comments and feedback. Although positive feedback was received from participants 
regarding the tools and potential of PervaLaxis 1, it was clear that there were both global and 
local (Dumas & Redish, 1999) usability issues. Global in the sense of the inherent limitations 
of the underlying technology, which although typical of smartphones at the time, were that the 
  
                               
 Chapter 3. Multi-Stage Proof-of-Concept Prototyping and Evaluation 
45 
 
joystick and the small keypad buttons were difficult to use, the screen was too small and the 
icons were not intuitive. Local in the sense of the PervaLaxis application which participants 
suggested could be improved with the addition of step-by-step injection instructions, 
confirmations for messages sent, a “panic button”, a mechanism to avoid false alarms for 
injections, more intuitive menus and icons, an easier way to add and remove AAIs in the 
expiry date list and a redesign of the locations tool which several found too difficult to use.  
 
     In summary, while the study was fairly informal, limited to only a few participants and 
without a control group, it provided some useful insights into the technological feasibility of 
smartphone tools and wireless sensing for anaphylaxis management and some useful 
formative feedback for the design of an improved prototype, PervaLaxis 2. 
 
 
3.5 Study two – PervaLaxis 2  
 
     The purpose of this study was to evaluate formative and summative usability of an 
improved technological proof-of-concept prototype, PervaLaxis 2, with a larger sample of 
participants. PervaLaxis 2 implemented the usability improvements identified in the first 
study. It was created in a newer touchscreen smartphone (HTC Diamond 2 with Windows 
Mobile 6.1) with a re-designed user interface. 
 
3.5.1 PervaLaxis 2 design 
 
Fig. 3.4 (left) depicts the use cases implemented in PervaLaxis 2 in the context of everyday 
life scenarios. PervaLaxis 2 included re-designed video tools (information about anaphylaxis), 
a re-designed expiry date tool with traffic light colouring (AAI management) and, 
importantly, the adrenaline injection sensing tool from study one developed into a more 
focused tool to support training together with an accompanying step-by-step guide (adrenaline 
injection training). The idea of generically sensing any injection events with real injectors 
may be something that could, in the future, be designed into next generation “smart AAIs” or 
smart add-ons for conventional AAIs, but the idea presents significant technological and 
implementation issues (not least concerns regarding false positive messaging). In addition, the 
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literature and the user feedback in study one identified a need for injection training support – 















Fig. 3.4 (right) shows the use cases implemented in PervaLaxis 2 in the context of an 
emergency scenario. PervaLaxis 2 tools were designed to support the user in case of 
emergency with videos about how to inject adrenaline and provided functionality with an 












Fig. 3.5 (a) PervaLaxis 2 smartphone device;  (b) AAI trainer with a three-axis BluetoothTM 
accelerometer; (c) Pen size comparison. 
 
                     
Fig. 3.4 PervaLaxis 2 support in everyday life (left) and emergency (right) scenarios. 
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The PervaLaxis 2 prototype was implemented in an HTC Diamond 2 touchscreen 
smartphone running Windows Mobile 6.1. Fig. 3.6 illustrates the PervaLaxis 2 Touchscreen 
smartphone and AAI trainer with wireless accelerometer unit, containing a SparkFun 
Bluetooth® Wireless 3D Tilt Sensing unit, battery and an LM7805 voltage regulator. The unit 
was configured to sample X, Y and Z channels at 10 Hz. Empirical thresholding limits were 
used to detect possible injections. The tools were developed using Visual Studio 2008, C#.  
 
        Fig. 3.6 shows screenshots of the PervaLaxis 2 user interface. The emergency button on 
the home screen (Fig. 3.6a) sends emergency SMS messages to emergency services and 
selected contacts with embedded location information. Fig. 3.6b shows the new AAI expiry 
date list with the traffic light colouring (red for out-of-date, yellow for near-date and green for 
in date) and equivalent emoticons; and Fig 3.6c shows the information tool with videos about 
anaphylaxis, injecting adrenaline, symptoms and what to do in an emergency. Fig. 3.7d shows 
the new injector trainer step-by-step tool showing simple steps about how to give an injection. 
This tool included sensing to help users practice injections by providing feedback on the force 
applied. The feedback was provided in step five of the guide after the trainer tool 
recommended 'swing and jab' of the AAI trainer. A 'happy face' icon was shown if the 
injection data (received from the wireless accelerometer on the trainer) indicated sufficient 












Fig. 3.6 (a) PervaLaxis 2 welcome screen and emergency button;  (b) Expiry date list;                      
(c) Videos; (d) Step-by-step AAI trainer tool. 
 
 
                               




     Table 3.3 summarises the full set of everyday and emergency tools implemented in 




    A usability study was undertaken with 32 participants aged 18 to 40 years old. While testing 
with healthy volunteers is appropriate for pre-clinical testing, and there is the further issue that 
the vast majority of anaphylactic people are still preteen minors, the opinions of test volunteers 
with allergy experience was of interest. For this reason volunteers were asked about their 
allergy experience and the group of 32 constituted 16 people without allergies and 16 people 
with experience of allergies, i.e., were allergy sufferers themselves or caregivers of a person 
with allergies. The reported allergies ranged from mild to significant but no participants were 
carriers of AAIs and none had experience of their use. All 32 followed the same test procedure 
but, for interest only, the results of those who had experience of allergy were compared to 






Fig. 3.7. Mechanism used to detect adrenaline injection events through an Auto-Injector 
trainer tool and a sensor mounted on an Epipen® AAI trainer device. 
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Manage the expiry dates 
of AAIs. 
Keep injectors in-date at 
all the times. 
 
AAI management. 
Injector expiry date list 
 
 
It was designed to 
manage (checking 
and modifying) a 
list of AAIs expiry 
dates. 













and feedback on 
sensed injection 
motion. 









services and carers about 
an emergency event. 
List of nominated 
people.  
 
Contact numbers (within settings) 
 
It was designed to 




Get informed about 
anaphylaxis management.                                           
Encourage continuous 
training about how to 
detect symptoms, how to 
avoid allergens, how to 









It was designed to 
provide 
information  about 
anaphylaxis and 








services and carers about 
an emergency event.  






location and event). 
- Sensing possible 
injections. 
Emergency support button 
 
It was designed to 
contact emergency 
services, sending 
SMS messages to 
emergency 
services and carers 
with the press of a 
button. Name, 
GPS location and 
event were 




     After signing consent forms, participants were provided with an explanation about 
anaphylaxis and adrenaline injections and were provided with documents on which this 
explanation was based. These included the manufacturer’s injector information leaflet showing 
how to inject adrenaline and two information leaflets produced by the Anaphylaxis Campaign 
UK about anaphylaxis, its causes, symptoms, treatment and emergency recommendations. 
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After consulting the documents, participants completed a system usability scale questionnaire 
(Brooke, 2006). They were then required to carry out four tasks with PervaLaxis 2 (Table 
3.4). After finishing each task, they completed a NASA TLX workload questionnaire (NASA, 
2003) and at the end of the evaluation they completed a system usability scale questionnaire. 
 
Table 3.4 Tasks undertaken in the usability evaluation of PervaLaxis 2. 
Task 1 
Videos 
The user was required to open PervaLaxis 2, select a specific video about 
anaphylaxis and return to the tools menu. 
Task 2 
Injector list 
The user was required to use the injector expiry date tool to create a list of 
three AAI expiry dates (one non-expired, one expiring and one expired), 
delete one expiry date from the list and to edit another. 
Task 3 
Trainer 
The user was asked to open the trainer tool, run the injection demonstration 





The user was required to press the emergency support button, watch an 
adrenaline injection video and simulate an injection using the injector trainer 
device.  
 
     ISO 9241-11 (Ergonomic of human system interaction– Part 11: Guidance on usability) 
(ISO 9241-11, 1998) guidelines were used to measure effectiveness, efficiency, and 
satisfaction.  
 
     During the tasks, participants could request assistance at any time. The number of requests 
was counted by the researcher. All requests were simple navigation queries. User keystrokes 
were automatically counted and logged by the system, and the task time was measured by the 
researcher. 
 
While undertaking the tasks, participants were encouraged to “think aloud” about their 
interaction with the system. They were particularly encouraged to make suggestions and to 
identify usability issues. All comments were recorded. Additional comments and suggestions 
were obtained from the completed workload and usability questionnaires and in a debrief talk. 
 
A Shapiro-Wilk test was used to test if results were samples of a normally distributed 
population (significance level = 0.05) (Field, 2000). Parametric t-tests were used on normally 
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distributed results; and Mann-Whitney and Friedman Rank tests for results not normally 
























3.5.3 System usability scale results 
     Fig. 3.8 shows the results of the system usability scale. These results revealed significant 
differences between PervaLaxis 2 and the traditional system for all 10 questions. Here 
references to the traditional system mean the traditional system alone, i.e., the initial in-person 
advice and training and provision of hardcopy documentation. References to PervaLaxis 2 
mean the PervaLaxis 2 prototype supplementing the traditional system. Participants rated 
PervaLaxis better than the traditional system when they were asked whether they thought that 
they would like to use the system frequently. They found the traditional system more complex, 
more difficult to use, less consistent and less integrated than PervaLaxis 2. They felt more 
confident using PervaLaxis 2 and felt they needed to learn less to get going with it.  
 
There were no significant differences between the results of allergic and non-allergic 
participants, with the exception of questions 4 and 10 where non-allergic participants reported 
 
Fig. 3.8 System usability scale comparison between the traditional system and PervaLaxis 2 
(N=32, there were significant differences in all the SUS questions, p<0.05). 
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more difficulty with the traditional system which, given their lack of allergy background, it 
might be anticipated.  
 
The average SUS score for the printed instructions was 51.4, while the SUS for PervaLaxis 2 
was 83.1. Rated according to Bangor, Kortum & Miller (2008:592), the results were 
encouraging; the traditional system SUS score was unacceptable (between poor and OK) and 
PervaLaxis 2 was acceptable (between good and excellent).  
 
3.5.4 Workload results 
     Fig. 3.9 shows the mental, physical and temporal demands, and the self-reported levels of 
performance, effort and frustration quantified using the NASA TLX scales. There were no 
significant differences between allergic and non-allergic participant results. Significant 
differences were found in the different scales for each task, as might be anticipated due to 
difference in keystrokes and actions required of each. But, although the time to complete each 
task was different, there were no significant differences in the temporal demand, suggesting 

















Fig. 3.9 NASA TLX scales results. 
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Creating a list of injectors had a higher mental demand in comparison with using the 
emergency support button. Significant differences in physical demand (X
2
(3)=31.39, p<0.05) 
were shown for different tasks, with the injection trainer and emergency action simulation 
tasks requiring the greatest demand.  Both these tasks required participants to simulate an 
injection. Furthermore, significant differences in performance (X
2
(3)=13.9, p<0.05), effort 
(X
2
(3)=22.46, p<0.05) and frustration (X
2
(3)=26.3, p<0.05), indicated that using the videos 
was an undemanding task, but creating an injectors expiry date list was much more 
demanding. The injector list task had the highest demand in four out of six TLX scales. This 
was somewhat expected since this task required the greatest numbers of steps, however, 
usability issues with the touchscreen keyboard were identified (e.g., the resistive screen of the 
smartphone device was too sensitive and caused participants to type incorrect characters). 
 
3.5.5 Results from ISO 9241-11 usability measures 
     The Mann-Whitney test showed, again, that there was no significant difference between 
allergic and non-allergic participants using PervaLaxis 2 in the ISO 9241-11 measures of 
effectiveness, efficiency, satisfaction and the amount of help provided to them. While 
satisfaction of allergic participants might have been expected to be higher than non-allergic 
participants, the satisfaction was high for both.  
 
The Friedman Rank test revealed significant differences between the effectiveness, 
efficiency and number of requests for assistance for tasks (Fig.3.10). For example, it can be 
seen in Fig. 3.10 that for task 1, using videos about anaphylaxis information, participants had 
significantly better effectiveness, better efficiency and asked for less help. This would mean 
that participants made less keystroke errors (i.e., were closer to the optimal number of 
keystrokes) and carried out this task quicker than the other tasks. In contrast, it is noticeable 
that the creation and editing of an injector list produced on average more keystrokes than the 
optimal number, needed more time to complete and required more navigation advice in 
comparison with the other tasks. The test also suggested that the perceived satisfaction was 
not significantly different within tasks with a visible average level around 80%. This would 
indicate that participants were satisfied with the implemented functionalities. 
 
                               







Fig. 3.10. (a-c) Measures of usability according to ISO 9241 part 11. (d) Amount of navigation 




The X2 indicates significant differences within tasks (figures a,b and d) or non-significant differences (figure c). 
 
Usability measures, considering all parrticipants combined (as there was not siginificant differences between groups): 
(a) Effectiveness: Accuracy and completeness with which users achieve specified goals. 
Effectiveness = (Correct number of keystrokes / participant’s number of keystrokes) *100 [%] (Range: 0 to 100) ; 
Where: The correct (i.e., optimal) number of keystrokes are: {Videos= 4; Injector list= 44; Trainer=13;Emergency button=4} 
(b) Efficiency: Resources expended in relation to the effectiveness with which users achieve goals, in this case time. 
 Temporal efficiency = Effectiveness * [( 
               
   
 
   
 )]  [% ] (Range: 0 to 100) 
Where: N:number of participants=32;     Optimal time=Expert’s time;     ti:Time of participant i. 
 
(c) Satisfaction: Freedom from discomfort, and positive attitudes towards the use of the application. 
Satisfaction with the implemented tools= (Subjective value) [%] (Range: 0:Very unlikely to 100:Very likely);  
Statements asked to participants about satisfaction with the implemented tools:  
-Videos: I think this tool could help people learn about the anaphylactic condition. 
-Injector list:I think this tool could help people manage their AAIs. 
-Trainer: I think this tool could train people using the AAI. 
-Emergency action simulation: I think this tool could help people to react correctly in an emergency event. 
 
(d) The number of requests for assistance was quantified by the researcher. They were the number of  times the participant received 
navigation advice per task. 
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3.5.6 Analysis of observations and comments 
     A content analysis was performed on the 257 comments transcribed and collated from 
participants “think aloud” commentary, questionnaire submissions and debrief. A thematic 
analisys was carried out. Comments were categorised according to their respective task and 
identified as one of the following themes: (1) positive statements about PervaLaxis 2; or 
comments or suggestions regarding (2) the user interface; (3) the hardware and (4) the 
Smartphone processing speed. A trained independent coder carried out a categorisation for 
reliability evaluation. The reliability between coders had a satisfactory Cohen’s kappa 
coefficient above 0.7.  
 
    Positive statements comprised 25% of the total. Participants reported that PervaLaxis 2 was 
interesting, useful for allergy management, preferable to the documents of the traditional 
system and that the information and functions were more accessible by being integrated in the 
mobile phone. 
 
     Thirty-four percent of the total comments provided suggestions related to the user interface 
and 33% related to functionality. Seven percent commented on low processing speed of the 
Smartphone (which was worsened by a monitoring connection with the researcher's 
computer). Participants commented on font size and colours, suggesting larger fonts and 
higher contrast colours, and suggested subtitles for the videos. Comments reflected that the 
smartphone navigation was initially demanding but soon became easier.  
 
     The injector list task had positive reactions in, for example, the use of emoticons to 
provide a simple indicator of injector expiry date (a happy face for each in-date injector and a 
sad face for an out-of-date injector), but participants suggested to improve the usability of the 
touchscreen keyboard. The emergency support button received positive comments. 
Participants liked the possibility of sending the SMS messages with a single button press, 
including the name, GPS location and event. Their suggestions included provision for 
recorded voice messages and that the emergency function might also involve making a phone 
call after sending the SMS message.  
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In recording results of participants’ injection attempts, errors were observed (deviations 
from the information and instructions provided) in injection site, not applying sufficient force, 
not holding the injector in place for ten seconds and not massaging the injection site. It was 
interesting to observe a reduction in these errors on the subsequent injection required in task 4 
(emergency action simulation), suggesting that practice and feedback from PervaLaxis 2 may 
have helped users improve their performance. For example, in the first injection in task 3, two 
participants held the injector the wrong way around and would have injected their own 
thumbs if the trainer had been a real injector. There were no such errors in the subsequent 
injection. Similarly, four participants failed to hold the injector trainer in place for 10 seconds 
after the first injection, but all performed correctly on the next injection. However, there were 
5 in 32 attempts in task 4 which failed to make sufficient force to make the correct “jab” type 
injection motion. 
 
The injector trainer testing demonstrated that the simple thresholding detection method was 
limited. For example, only 20 (out of 32) of the injection attempts were correctly detected on 
the first occasion (task 3); and 25 out of 32 in the second occasion (task 4), with only five 
potentially accounted for by user error. An improved method of detection would not only 
improve reporting of possible injections but would reduce the possibility of false positive 
events. 
 
3.6 Study three – PervaLaxis 3 
     PervaLaxis 3 implemented suggestions collected from the previous study; aesthetic 
changes in background colour, increased font sizes, including the ability to begin a phone call 
with the emergency button, the inclusion of an Allergy Action Plan, and, importantly, the 
addition of an AAI manufacturer video animation with added subtitles within the injection 
trainer step-by step tool (Fig 3.11). The enhanced step-by-step tool was used in this third 
study to evaluate its potential for adrenaline injection training in comparison with traditional 
care paper-documents. This was a slightly more formal evaluation of the functions 
implemented in PervaLaxis 3 to quantify the benefits of smartphone tools designed for 
adrenaline injection training. It was hypothesised that smartphone tools with video animations 
may produce better adrenaline injection performances. 
 
                               

















     Twenty-two healthy adult participants signed a consent form and answered a questionnaire 
about mobile phone usage. They were briefed on anaphylaxis and AAI use and randomly 
assigned into two groups (balanced in a first come first served basis) as follows: a control 
group provided with manufacturer paper-document injection instructions and a technology 
group provided with the same manufacturer instructions, but implemented with a video 
demonstration and a visual step-by-step guide in PervaLaxis 3. Participants used their 
allocated practice material with an AAI trainer before demonstrating use and completing a 
technology acceptance questionnaire. Correct technique required each of four steps 
recommended by the AAI manufacturer and used in previous studies (Arga et al., 2011; 
Sicherer, Forman & Noone, 2000) as follows: removal of the injector trainer safety cap, 
'swing and jab' motion of the injector trainer to outer thigh, holding the trainer in place for 10 
seconds and massaging the site of the injection for 10 seconds  
 
The evaluation sessions were video recorded. Sessions lasted a maximum 30 minutes. The 
videos were analysed using ELAN annotation software. Another posgradute researcher 
researcher carried out an independent review of a random sample of videos (Cohen’s Kappa 
above 0.7). A Shapiro-Wilk test was used to test if results were samples of a normally 
distributed population (Significance level = 0.05) (Field, 2000). Parametric t-tests were used on 
 
Fig. 3.11 AAI trainer tool for adrenaline injection training:                                                                                                    
(a) Step-by-step trainer interface; (b) Video animation with subtitles. 
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normally distributed results; and Χ
2
 and Mann-Whitney (U) tests for results not normally 
distributed. The statistical tests were undertaken using SPSS® version 21.  
 
3.6.2 Participants 
    Twenty-two healthy participants were recruited from the University of Birmingham, UK. 
People with prescribed AAIs, anaphylactic people and their carers were not included in the 
study. Participants were all students, the average age in both groups was 22 years old. Some 
participants reported having mild allergies (i.e., hay fever) but none of them reported having 
an AAI or having experience of their use.  All but three of the participants had smartphones.  
 
3.6.3 Results and conclusions 
     Significantly more people in the technology group (63.6%) completed all injection steps 
correctly compared to those in the control group (18.2%) (X²=4.701, p<0.05). The technology 
group (81.8%) also performed significantly more correct the 'swing and jab' step than the 
control group (45.5%) (X²=3.143, p<0.05). Technology acceptance questionnaire results 
showed that the technology group reported more usefulness of their smartphone practice 
material than the control group (U=7.5, p<0.001), they also reported better ease of use (U=10, 
p<0.01) and more willingness about future use (t(20)=5.661, p<0.001).  Feedback from the 
technology group suggested the visual demonstrations helped in modelling the correct 
technique.  
 
     In summary the results suggested that smartphone technology may help improve AAI 
training.   
 
3.7 Summary 
    The first study provided useful insights into technological function and feasibility as well 
as user needs and usability issues which all usefully informed improvements made in 
PervaLaxis 2. The second study demonstrated the potential of this new prototype to support 
anaphylaxis management and training by supplementing the system of traditional care. The 
final study was more informative about the potential for AAI training through a step-by-step- 
tool and a video animations.  
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    However, the studies presented in this chapter were more technological proof-of-concepts 
rather than clinical proof-of-concepts. They provided encouraging results, helped understand 
user needs, helped map these onto smartphone tools and helped identify usability issues. But 
the prototypes did not benefit from participatory design and there was no collaboration or 
participation with expert clinicians and, hence, no clinical evaluation of the systems. In 
addition the designs were not purposefully grounded in self-efficacy theory, though sources of 
self-efficacy were contained in the tools. For example, the use of video animations was a 
source of vicarious experience (modelling) and the step-by-step training tool contained a 
source of enactive experience (mastery skills). The limitations outlined here were addressed in 
further work involving the design and evaluation of a prototype, AllergiSense, that was closer 
to a clinical proof-of-concept prototype. AllergiSense design and evaluation results are 










AllergiSense Design                     
 
4.1  Introduction 
     This chapter describes the design of AllergiSense, a mobile application for anaphylaxis 
management designed with a more formal methodology and evaluated in more detail. The 
PervaLaxis studies presented in the previous chapter were technological proof-of-concepts. 
They provided encouraging results, helped provide insights into user needs, helped map these 
into smartphone tools and helped identify usability issues. But PervaLaxis prototypes did not 
benefit from participatory design and there was no collaboration or participation with expert 
clinicians and, hence, no clinical evaluation of the systems. In addition the designs were not 
purposefully grounded in self-efficacy theory.  
 
    AllergiSense started afresh in terms of design and in terms of clinical collaboration, and 
with an ambition to produce something closer to a clinical proof-of-concept prototype. The 
AllergiSense design methodology adopted is not one that has been reported in the literature. It 
is tentatively proposed as an incremental improvement to prototyping methodology and, in 
particular, for pervasive health prototyping. The methodology involves the development of 
near-clinical proof-of-concept prototypes from a combination of participatory design together 
with the embedding of self-efficacy sources.  
 
   The AllergiSense participatory design involved focus groups comprising allergy specialists, 
a trained anaphylactic person, carers and a smartphone app designer. The tools proposed via 
the process were supplemented with embedded sources of self-efficacy that were evolved 
through further participatory design.  
 




   This chapter is organised as follows: Section 4.2 presents the methods used in the design of 
AllergiSense, provides results of the participatory design focus groups and explains the tools 
and functionalities implemented in the mobile application. Section 4.3 explains the simple 
algorithm developed to use wireless sensor data from adrenaline EpiPen® trainer injections to 
assess injections in the AllergiSense trainer feedback tool. And section 4.4 summarises the 
main findings of the design process. 
 
 
4.2 Design of AllergiSense application 
4.2.1 Research procedure 
 
     Two focus group sessions were convened at the University of Birmingham UK. The 
participants included allergy specialists, an anaphylactic person, carers of anaphylactic people 
and a smartphone app designer. Each focus group session lasted one hour and the two 
sessions were one month apart. The aim of the focus groups was to gain a deeper 
understanding of anaphylaxis management needs and to involve the participants, as potential 
users and stakeholders, in the design a mobile application to support those needs. The aim 
was not to reach a consensus but to elicit rich and varied accounts from different perspectives. 
All participants were encouraged to participate and the discussion was generally well-
balanced between the participants. The researcher acted as the moderator to ensure this 
balance and another researcher took notes. The format was generally relaxed and informal and 
participants were provided with coffee and refreshments.  
 
     The focus group participant profiles are presented in table 4.1. There was an allergy 
clinician, an allergy nurse, a trained anaphylactic person, two carers and a healthy participant 
(who researched anaphylaxis prior to the sessions) with an engineering background and with 
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Table 4.1. Profiles of focus groups participants 
Participant Gender Age Status Smartphone use 
1 Female 31-40 Allergy clinician 
Reported using an iPhone, social 
networking, e-mail and media 
apps. 
2 Female 41-50 Allergy nurse Reported using an iPhone, mapping 
and social media apps. 
3 Female 51-60 Trained anaphylactic person 
Reported using a Nokia 
smartphone using social 
networking apps. 
4 Female 41-50 Carer of an anaphylactic 
person 
Reported using a Samsung 
smartphone and several apps. 
5 Male 41-50 Carer of an anaphylactic 
person 
Reported using a non-smartphone, 
(but with communication and 
programming expertise)  
6 Male 21-30 
Healthy participant with an 
engineering background and 
experience in smartphone 
apps. (Researched anaphylaxis 
before the sessions) 
Reported using a Google 
smartphone and several apps and 
using SMS messages and phone 
calls very frequently. 
 
 
First focus group. Participants were provided with a short introduction about the aim of the 
meeting. After agreeing to participate, they read and signed consent forms. Participants were 
then asked to briefly introduce themselves to the other group members. A detailed explanation 
of mobile apps was provided and PowerPoint® slide examples of apps for allergies and for 
anaphylaxis were presented. Participants were allocated in groups of two (three pairs), group 
one was formed by participants one and five (the allergy clinician and a carer), group two 
included participants two and three (the allergy nurse and the anaphylactic person) and 
participants four and six formed group three (a carer and a healthy participant). The first 
activity in this focus group was to undertake a brainstorming needs analysis exercise about 
anaphylaxis management. Ideas were summarised on a white board by the researcher 
(moderator) and notes were taken by another researcher. Participants were asked the 
following questions: who would use mobile apps for anaphylaxis management?, what or how 
could those tools support? and where would they be used?. All participants were encouraged 
to participate. The second part of this focus group consisted of each group designing paper 
prototypes for two different tools identified in the brainstorming exercise. They used the 
paper mock-up PICTIVE
1
 participatory design technique (Muller, 1991), for which they were 
provided coloured pens and paper, post-it notes, “smiley faces” and “star” stickers, glue, 
                                                          
1
 Plastic interface for collaborative technology initiatives through video exploration (Muller, 1991) 
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scissors and other stationery (as shown in Fig. 4.1) to stimulate their imagination. The session 
was video recorded for analysis. Users were asked to write on a large piece of paper the 
anaphylaxis management challenges, the goals of the tools and the tasks involved with the 
tool. They used post-its to create a storyboard of the tool design in a domino style (i.e., a 
sequence of post-its representing the order in which the screens would appear) and used an 
old PDA cover to frame and size the post-it screens (as shown in Fig 4.2). Finally, each group 
was asked to explain their tools to the group using the PDA cover framed screens. Group 










Fig. 4.1 PICTIVE set up of the focus groups. 
 
 





Chapter 4. AllergiSense Design 
64 
 
Second focus group. The aim of this focus group was to receive suggestions and identify 
preferences for user interface designs incorporating the ideas and tools described by 
participants in the first focus group session one month before.  The user interface mock-ups 
produced for this session were created with Balsamiq® software for higher fidelity user 
interface prototyping of screenshots with the look of a smartphone app (examples are shown 
later in Fig. 4.5). The same six participants attended the session. The initial activity was a 
brief review of the ideas and suggestions identified in the first focus group. Then, participants 
reviewed the look of the implemented mock-up tools and gave their suggestions. At the end of 
the focus group participants were asked to decide among different user interface styles and 
were asked to suggest a name for the mobile application.  
 
4.2.2 Results of the first focus group 
 
     The anaphylaxis management needs identified and discussed by participants in the first 
focus group are summarised in table 4.2. These were generally consistent with the user needs 
established less formally in the PervaLaxis studies, but were provided with more supporting 
detail as outlined below. 
 
    Participants identified two main contexts: emergency and everyday life. And they identified 
five main needs in anaphylaxis management, the need for: help educating others, help with 
communication, help with AAI use and management, help with food label checking and help 
with emergency situations. 
 
Table 4.2 Anaphylaxis management needs. 
User need Who About what How (with technology) Where 







-The condition  
-The treatment  
-The management   
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-Day to day management 
-Support groups (->Link to 
the Anaphylaxis campaign 
website) 










-Patient (child and 
adult), carers, 
relatives, 









-Know when to inject 
(detect symptoms) 
-How to use it 
-When to use it 
-What to do next 




   Emergency plan: 
   -Remove the 
    allergen 
   -Re-assess 
    (inject after 5 
     minutes) 
   -Go to hospital 
 
 
-How to manage AAI 
in everyday life with 
reminders about: 
- the AAI 
   -in date 
   -have it 























-Everyone can contribute 

















-In an actual 
emergency 
 
-In everyday life  
for training 
-Improving communication 
-Using AAI correctly 















Help educating others. Participants explained that people who might need to support the 
anaphylactic person needed to be educated about the condition, the treatment, the 
management and what to do in an emergency. They reported that this education could usefully 
take place in the allergy clinic, and also at home, at the school or anywhere as needed outside 
home (e.g., in an airplane or restaurant). They suggested this could be supported with text, 
video, audio, or any type of instructions and reminders.  
 
Help with communication. According to participants, anaphylaxis management in an 
emergency and in everyday life requires supporting patients, carers, and relatives in 
communications with emergency services (e.g., knowing what to do and what to say), with 
support groups and with allergy specialists. They suggested implementing a mechanism to 
contact emergency services and links to support group web sites and contact numbers for 
allergy services. 
 
Help with AAI use and management. People in the focus group reported the needs relating 
to AAI use and management in emergency and in everyday life, for example, tools for 
emergency situations to help decide when to use an AAI, how to use it, what to do after the 
injection, know what not to do (e.g., to avoid self-injecting the thumb), and to have 
emergency actions that includes instructions about removing the allergen, use of another AAI 
after 5 minutes and to go to hospital. For everyday life situations they suggested reminders to 
keep AAIs in-date, to have AAIs with them, to check the colour of the adrenaline (to check it 
is not cloudy which could indicate spoilage). 
 
Help with food label checking. Participants reported a need to detect harmful allergens in 
food ingredient labels and, to a lesser extent, in other products (e.g., contact allergens like 
latex in gloves). They mentioned food label checking could be supported with barcode 
reading and a central database that collects, stores and maintains records. They suggested that 
everyone could contribute. They also suggested a link to support groups and an information 
tool to support allergen avoidance. 
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Help with emergency situations. Focus group participants mentioned that patients, carers, 
relatives, friends, school teachers and work colleagues need a solution that supports them in 
emergency situations, for example, helping with AAI use, improving communication with 
emergency services and assessing the situation. In addition they needed a mechanism in 
everyday life to support them prepare for an emergency, e.g., training in AAI use, knowing 
how to assess an anaphylactic situation and knowing what to do. 
 
     After discussing anaphylaxis management needs, participants worked in groups of two to 
design the tools that supported their needs as follows: 
 
     Group one designed a simple education tool comprising a list of videos (their notes are 
shown in Fig. 4.3). They also designed a tool supporting food label checking. They 
envisioned the idea of using barcode reading to automatically detect allergens in food 
ingredients, informing the user if something contained an allergen, and also reporting any 
commonly cross reactive allergens (allergens that frequently co-occur, for example, other nuts 
with peanuts), processing large amounts of database products and ingredients with product 












Fig. 4.3 Participant paper mock-ups of everyday life tools. 
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      Group two designed a tool for the assessment and treatment of emergency situations (Fig. 
4.4 left). They created a list of possible symptoms that could indicate an anaphylactic 
reaction. This group suggested the implementation of video animations and step-by-step AAI 
instructions. They also suggested support for contacting emergency services with either 
automated calling support or sending a message with the GPS location of the patient. 
  
     Group three designed a tool for AAI management (Fig. 4.4 right). They wanted to support 
users in having their AAI/s available, not expired, knowing when to use them, trained in the 
correct steps of AAI use and knowing how to obtain help after using it. This tool overlapped 
the management of the AAI in everyday life and in emergency. They made a three-button 
menu screen comprising traffic-light coloured buttons: a yellow button to explain AAI use 
through pictures and instructions, a green button to be prepared for emergency with a 
















Fig. 4.4 Support in emergency (left), AAI use and management with emergency button 
(right).  
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4.2.3 Results of the second focus group 
 
     The user interface mock-ups produced for the second focus group were created with 
Balsamiq® software for higher fidelity user interface prototyping of screenshots with the look 
of a smartphone app. The participant feedback and paper mock-ups informed the designs. It 
was a challenging task to develop designs incorporating the many different ideas given by the 
participants. The solution to this was to create different alternatives for the participants to 
compare and choose from.  
 
     In addition to the tools suggested in the first focus group, an AAI injection training tool 
was created. A simplified version of an injection force sensing tool had been tested in the 
PervaLaxis prototypes, but while help with AAI use had been suggested, a sensing tool with 
feedback had not been explicitly suggested in the first participatory design session. This new 
version of the AAI injection training tool was designed purposefully to increase self-efficacy 
sources: it encouraged mastery and provided social persuasion (via encouraging assessments). 
The tool was included in mock-ups presented in the second focus group for participant 
feedback and is described in more detail in the section 4.3.  
 
     Fig. 4.5 shows some of the alternatives that participants were provided with. For example, 
the placing of the menus and the emergency buttons at the top or at the bottom of the screen 
(Fig. 4.5a and d), the use of “smiley faces” or tick and crosses in the training tool feedback 
(Fig. 4.5b) and the use of bar type buttons over the use of icon type buttons (Fig. 4.5c). 
Participants preferred to put the anaphylactic emergency button (Fig. 5.5a) and the cancel 
button (Fig 5.5d) at the top of the screen to improve their visibility and to avoid pressing them 
by mistake. They decided to have horizontal bar coloured buttons on the everyday life tools 
screen instead of icons (Fig. 5.5c). And for the injection training feedback tool, they preferred 
ticks and crosses rather than happy or unhappy faces because they thought they were clearer, 




































Fig. 4.5 a) Anaphylactic emergency button location; b) Decision between using smiley faces 
over tick and crosses in a injection training tool; c) Choosing between bar type buttons over 
icons type buttons; d) Decision to place a cancel button on top instead of at the bottom to 
avoid mistakes. 
      
     
a)            b)   
c)  d)  
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     Although participants suggested names for the application, for example, Ana-Smart, 
AllergyMate, Anadroid, EpiTOME (Training, organisation, management and emergency), it 
was decided, that AllergiSense was best because it combined three important characteristics 
of the mobile application that differentiate it from others: “Allerg” from anaphylactic 
allergies, “i” from interactive and “sense” from the use of wireless sensors in the AAI trainer.  
 
4.2.4 AllergiSense  
 
      Six tools suggested by participants were implemented in AllergiSense. Four tools for 
everyday life and two for emergency scenarios. These tools were selected as those which 
could be more reasonably and more readily implemented. For example, the barcode scanning 
of ingredients was not implemented. This was suggested to help with food label checking by 
automatically recognise the allergens. It is an idea that was announced as a future service in 
the UK, but has since been abandoned. Perhaps because it is an idea that requires cooperations 
and infrastructures that do not exist. Table 4.3 shows a summary of the tools and the 
functionality implemented for each.  
 
Table 4.3 AllergiSense tools. 




AAI expiry date manager 
 
It was designed to manage (checking and 
modifying) a list of AAIs expiry dates with 
“smiley” and “unhappy” faces and reminders. It 
implemented a traffic light colours code for the 
icons. 
Information: AAI step-by-step 
instructions 
It provides step-by-step injection instructions and 
a video. 
Information: videos 
It provides information videos about AAI use and 
how to recognise the symptoms of anaphylaxis 
AAI injection training (with 
feedback) 
It was designed to provide feedback about the 
steps of a simulated injection. The smartphone 
tool connects to wireless sensors mounted on an 
AAI trainer device. 
Emergency 
Emergency messages tool and 
call to 999 button 
They send text messages to emergency contacts 
and call 999 respectively. The name of the user, 
GPS location and event are embedded in the text 
messages. 
Emergency information: 
emergency what to do tool and 
AAI injection stepstool 
They provide information about emergency 
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    Fig. 4.6 shows screenshots of AllergiSense tools implemented for everyday life including 
an expiry date list, information about AAI use with step-by-step instructions, information in 
videos and injection training with feedback. While tools for an emergency, included 
information about emergency procedures and AAI use (in a list and with step-by-step 
instructions), and communication with emergency services and emergency contacts (SMS text 

























Fig. 4.6 AllergiSense tools for everyday life. 
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     Fig 4.7 shows the tools for emergency. The colouring of screens and buttons indicates if 
they are for emergency management (red) or for everyday life management (green). They 
were implemented in an Android smartphone. Android platform was chosen for three reasons: 
because at the time of writing Android was a very popular OS in the smartphone market, 
because the development tools and the smartphone devices cost were more accessible for 
























Fig. 4.7 AllergiSense tools for emergency. 
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  Table 4.4 compares the self-efficacy sources suggestions from the user needs inputs (from 
last chapter studies one to three, and from this chapter both participatory design sessions), by 
the traditional care paper documents, by AllergiSense tools excluding an injector tool with 
feedback and by AllergiSense. It can be seen that the user suggestions improve on the self-
efficacy sources compared to traditional care paper documents. 
 
     Very possibly without realising, participants proposed tools that could enhance their levels 
of self-efficacy. But, of course, people might intuitively ask for pictures or videos so that they 
can more easily copy (model) something they need to do. This suggests that participatory 
design in pervasive healthcare might more naturally ground solutions in self-efficacy theory, 
or at least help with contributing some sources of self-efficacy.   
 
Table 4.4 Self-efficacy sources supported by suggestions from user needs inputs, by the 
traditional care paper documents, by AllergiSense tools excluding an injector tool with 
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4.3 Injection sensing  
     This section describes how the steps of practice adrenaline injections with a trainer can be 
automatically recognised and evaluated. The functionality described here was implemented in 
the AllergiSense adrenaline injection training tool. 
 




     A wireless three-axis accelerometer sensor mounted on a trainer device was used to sense 
injection motion. Acceleration data was transmitted to AllergiSense application via 
Bluetooth™ . 
 
4.3.1 Preliminary results 
 
     Previous implementation results from attempts at injection sensing were useful in 
informing the design of this tool. These earlier implementations used an accelerometer sample 
rate of 10 Hz and a binary tree model for detection but achieved an accuracy of only 63%. 
Improved detection was desirable. The sample rate was increased and a sensor was added to 
the safety cap of the trainer to detect if the cap was removed, rather than relying only on 
acceleration data that did not provide precise information about this step of the injection.  
 
4.3.2 Hardware and sensing method 
 
     In the preliminary testing, the SparkFun sensing unit (described in chapter 3) comprised a 
PIC® microcontroller, a three-axis accelerometer and a Bluetooth™ transceiver. However, 
their size and shape was not convenient for evaluation purposes and was rather bulky for 
people to handle. Therefore, a new sensing unit, shown in Fig. 4.8, was designed and 
implemented. It included an Arduino "Pro mini" microcontroller, a three-axis accelerometer, a 
Bluetooth™ transceiver and a push button sensor under the blue safety cap to sense when it 
was removed. The sensing unit was encased in a slim plastic cover that was more easily 
handled. The accelerometer sensor unit was configured to sample X, Y and Z acceleration 
channels at 70 Hz. The communication with the smartphone device used a Serial Port Profile 
(SPP). A sampling rate of 70 Hz, was empirically selected as sufficiently high to improve 
sensing fidelity and that could be sustained in terms of battery life (approximately 3 hours of 

























Fig. 4.8 AllergiSense sensing unit mounted on an EpiPen® AAI trainer device. 
 
     In chapter 3, PervaLaxis studies, the injector sensing tool using acceleration data to detect 
possible injections was received very positively. However, it was limited to the detection of a 
'swing and jab' motion with a simple thresholding method that did not provide any 
information about two of the other important steps (removing the blue safety cap and holding 
the injector firmly in the place of the injection for 10 seconds). Therefore, a simple binary tree 
model that informed the status of the sensing unit was created and later implemented in 
AllergiSense smartphone (illustrated in Fig. 4.9) as follows: 
 
1. Creating the model 
1.1 Sensing data (from the allergy specialist collaborator) were collected by the AAI 
sensing unit and sent to a PC hyperterminal using Bluetooth™ protocol (training data). 
1.2 Features of acceleration data were calculated in the PC and saved in a CSV (i.e., 
comma separated value) file. The features of acceleration data were a set of statistical 
parameters representing continuous segments of X, Y and Z acceleration data over the 
time domain (they are described in the next section). 
1.3 The features were introduced into WEKA software (WEKA, 2012) to create a model 
that could classify features of acceleration over time into injection steps.  
 
2. Using the model 
2.1 The model created previously was implemented in AllergiSense. 
2.1 XYZ data from the user’s training injection were collected and sent to AllergiSense 
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through the AAI sensing unit.  
2.2 Features of user’s acceleration data were calculated in AllergiSense 
2.3 The model created previously classified the features of acceleration user’s data into 
segments of injection steps over time. 
2.4 Three types of motion could be detected: A 'swing and jab' motion (when the features 
of data represented the signature of a sudden and strong motion), a 'still' status (when the 
features of data represented a motionless sensing unit) and other motion labelled as 
'moving' (when the features of data represented a random type of movement). 
2.5. The array of segments of injection steps over time were later provided to a higher 
level decision tree model. The higher level model looked for the correct segments of  
injection steps over time and verified  that they were in the sequence required by a 
successful injection.  
 
 
Fig. 4.9 Creating and using a model for adrenaline injection feedback. 
 




4.3.3 Creating a classification model with WEKA software 
     The creation of a classification model was needed to translate X, Y and Z acceleration into 
injection steps. For this, acceleration data (training data) was required from a reliable person 
serving as gold standard for the injection steps. These were provided with the expert clinical 
collaborator. Classification algorithms can be based on different data mining techniques (e.g., 
binary trees or Bayesian classifiers), which can vary in complexity and in processing 
demands. Methods can be implemented in different programming languages (e.g., C# or 
Java), however, there are several research tools available that optimise this process. WEKA 
(2012) is one such popular freeware data mining tool. It provides a large variety of data 
mining techniques and was useful to obtain a classification model needed in this research.  
 
Recording training data. Training accelerometer data from 12 practice injections made by 
the expert clinical collaborator were recorded in a laptop using a hyperterminal interface 
wirelessly connected to the sensing unit. The injections were performed with the right hand, 
both sitting down and standing up to collect a range of training data that reflected usual body 
postures in adrenaline injection training scenarios. The injections included all the steps of the 
injection, namely remove the blue safety cap, inject firmly into the outer thigh at 90 degrees, 
hold in place the device for 10 seconds, remove the injector trainer and massage the area of 
the injection for 10 seconds. 
 
Extracting the features from the training data. In order to create a classification model 
with WEKA software, features of XYZ acceleration data in the time domain had to be 
calculated (since standard classification algorithms cannot take XYZ acceleration data 
directly). Therefore, the XYZ acceleration data of the training injections were transformed in 
a series of time segments of data with associated features (Kwapisz, Weiss and Moore, 2010). 
A sampling frequency of 70 Hz enabled a good trade-off between battery consumption and 
noise level, thus the use of filtering techniques like those in (Zhang et al., 2010) were avoided 
to decrease calculation demands in the smartphone.  
 
     A set of 24 features of data were generated per segment of 70 samples of XYZ acceleration 
(25 for the training data, which included a pre-selected class). Each segment had a sliding 
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window of one second and a 50% overlap. One second was considered enough to detect the 
“swing and jab” step (the moment of the injection) with 70 rows of XYZ samples, while the 
50% overlap was chosen because it was useful to avoid the loss of meaningful data located on 
window edges (Wang and Chen, 2005; Devaul and Dunn, 2001).  
 
     Table 4.5 lists the features calculated per segment of XYZ acceleration data. Average, 
standard deviation, and maximum and minimum values have been used in activity 
classification research using accelerometers (Saponas et al. 2008, Kwapisz, Weiss and Moore, 





Table 4.5 List of features per segment of acceleration data. 
Feature                                       
(70 xyz samples; 1 second of 
data) 
Features generated 
from XYZ data  
Description 
Average  xaverage, yaverage, 
zaverage 
Average acceleration per axis 
Standard deviation xsd, ysd, zsd Standard deviation per axis 
Average resultant Raverage 
         
                     
  
 
        
  
 
Standard deviation of the 
average resultant 
Rsd 
             
                     
  
 
Maximum value xMax, yMax, zMax, 
RMax 
Maximum value per axis and per resultant 
Minimum value xmin, ymin, zmin, 
Rmin 
Minimum value per axis and per resultant 
Average absolute difference 
(average of the distance to the 





                
                   
  
 
Same expression per dYaverage, dZaverage and 
Raverage 




Maximum value minus minimum value per axis and 
resultant 












































Fig. 4.10 XYZ acceleration data with all the steps of the injection (top), gold standard injection from 
the clinical collaborator with a simplified version of steps (bottom).  
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     In the preliminary injection pilot study, mentioned before, all the steps of the injection 
(removing the safety cap, moving the injector towards the outer thigh, 'swing and jab', stay 
still for ten seconds and remove the injector) were considered for sensing and classification 
(see the top of Fig 4.10). However, a low accuracy of 63% was found and many of the steps 
were confused in the model. Therefore, to increase the accuracy of the classification 
algorithm, and to minimise the confusion among steps, only three types of motion were 
further considered: The 'swing and jab' movement when the injection is done, the motionless 
state when the person hold the injector still for 10 seconds and any other type movement 
(labelled as 'moving') (see the bottom of Fig. 4.10). While the removal of the safety cap was 
sensed with a specific purpose sensor (a push button placed under the safety cap).   
 
4.3.4 Classification model accuracy 
      Once the features of the acceleration training data were calculated, a binary decision tree 
(J48) data mining technique was chosen in WEKA software. J48 is the Java implementation 
of popular data mining C4.5 decision tree algorithm. It was chosen because it can be feasible 
to implement in the resource constraints of mobile devices, such as smartphones. The 
accuracy of the model created in WEKA was 88%. This accuracy was considered sufficient 
for AAI training scenarios (unlike the much higher accuracy that would be needed of real 
injection sensing) but, of course, other contributions to the area could be useful in improving 
further. This accuracy was obtained with a simplified version of steps (illustrated at the 
bottom of Fig. 4.10) in direction of the Y-axis, which is the axis along the length of the 
trainer. Axes X and Z were discarded from the model as they provided limited information in 
the sensing of the injection. 
Table 4.6 Confusion Matrix of the model created by WEKA. 
 
moving jab still classified as 
48 2 4 moving 
5 12 0 jab 
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The classification model implemented in the AllergiSense was as follows: 
 
=== Classification model  === 
 
dYaverage <= 1.933061: still  
dYaverage > 1.933061 
|   ymin <= 153 
|   |   dYaverage <= 37.37602: jab  
|   |   dYaverage > 37.37602: moving  
|   ymin > 153 
|   |   ysd <= 12.774451 
|   |   |   yMax-ymin <= 50: moving  
|   |   |   yMax-ymin > 50 
|   |   |   |   dYaverage <= 4.609694: still  
|   |   |   |   dYaverage > 4.609694 
|   |   |   |   |   yMax-ymin <= 99: moving  
|   |   |   |   |   yMax-ymin > 99: still  
|   |   ysd > 12.774451: moving  
 
     It can be seen that the number of features required by the model to detect the steps of the 
injection was considerable less than the original features proposed in table 4.5 (only 6 out of 
24). This was a benefit obtained by the utilisation of the J48 decision tree algorithm, which 
removed (‘pruned’) the less useful features (under the consideration that Y was the main axis 
affected in the injection motion). 
 
4.3.5 Providing feedback about the steps of the injection 
    After creating the classification model, it was implemented in AllergiSense. The process of 
providing feedback involved three steps: 
 
1. Collect acceleration data from the user injection and calculate their features. 
2. Provide the features to the classification model. 
3. Use a higher level model to know if the sequence of steps, in segments of injection steps 
over time resulted from the classification model, reflected a possible injection. 
 
     The higher level model was a simple implementation that looked first for the steps of the 
injection over time, and later, verified they were in the following sequence: 
moving + swing and jab + still (for 10 seconds) + moving, 
which represented a possible injection of adrenaline. 
 





Fig. 4.11 AllergiSense injection training feedback.  
 
     AllergiSense users received injection feedback as illustrated in Fig. 4.11, including 
information about the safety cap removal, the way the injector was held, whether the 'swing 
and jab' motion was detected and if the injector was held in place for 10 seconds. Information 
about the place of the injection and the correct massage time were collected with a short 
questionnaire before providing feedback. 
  
4.4 Summary 
     This chapter showed how AllergiSense was designed based on participatory design focus 
groups with allergy specialists, anaphylactic people, carers and smartphone users. Participants 
expressed their user needs and created and refined paper prototypes based on these needs. 
Later, AllergiSense tools that incorporated suggestions from the focus groups together with 
purposefully added sources of self-efficacy were presented. These included a novel tool for 
adrenaline injection training feedback. Results from the evaluation of the AllergiSense tools 
are presented in the following two chapters. 
 
                               






Evaluation of AllergiSense Adrenaline 




     The purpose of this chapter is to provide the results of formal laboratory evaluation of 
AllergiSense, the final anaphylaxis management smartphone prototype whose design was 
described in the last chapter. AllergiSense was designed with embedded sources of self-
efficacy and, in particular, to support AAI training by sensing injection practice with wireless 




     The aim of this evaluation was to carry out a three-arm, pre-post (two-week), randomised 
controlled study with healthy participants to investigate whether smartphone tools for 
adrenaline injection training could improve adrenaline injection performance and positively 
influence injection self-efficacy.  
 
     The main hypothesis of this evaluation was that using AllergiSense (in addition to 
traditional care paper documents training) would provide better adrenaline injection skills in 
comparison with training supported by traditional care paper documents alone.  
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     The primary outcome of this research was an assessment of the effect of different training 
materials on adrenaline injection skills through the evaluation of the injection steps based on 
the manufacturer’s instructions.  The secondary outcomes were to evaluate participants’ self-
reported AAI self-efficacy, workload, usability, system usefulness, ease-of-use and attitudes 
towards use. 
 
     The study received ethical approval from the Science, Technology, Engineering and 
Mathematics Ethical Review Committee of the University of Birmingham UK (ERN_13-
1496) and was funded by The Anaphylaxis Campaign’s Small Grant Scheme (04-13-LHM). 
Additionally, the training provided was clinically approved and the procedure overseen by an 




A Shapiro-Wilk test was used to test if results were samples of a normally distributed 
population (Significance level = 0.05) (Field, 2000). Parametric t-tests and ANOVA were used 
on normally distributed results; Friedman's Rank  and Mann-Whitney (U) tests for results not 
normally distributed and Χ
2
 for comparing frequencies of data. The statistical tests were 
undertaken using SPSS® version 21.  
 
5.2.2 Participants 
     
     Twenty-one adult participants per group (63 in total) were trained in the use of an Epipen® 
AAI with an Epipen® trainer injector. Participants were recruited from the University of 







                                                          
1
 The recruitment of anaphylactic people and their carers, i.e., of patients, would have required extensive NHS 
and ethical permissions. Approval for testing of technology with real patients would be more likely in the event 
of positive outcomes from testing with healthy participants. 
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5.2.3 Assessment of performance and administered questionnaires 
 
 Assessment of adrenaline injection performance. The assessment of AAI performance was 
based on the marking scheme used in other studies (Sicherer, Forman & Noone, 2000; Arga et 
al., 2011), which, in turn, was based on the steps recommended by the EpiPen® AAI 
manufacturer. These are: 
1. Remove the blue safety cap. 
2. ’Swing and jab’ the orange tip of the AAI trainer against the outer thigh until it 
'clicks'.   
3. Hold firmly against the thigh for 10 seconds. 
4. Remove the Auto-Injector from the thigh. The orange tip will extend to cover the 
needle and massage the injection area for 10 seconds. 
 
   The AllergiSense system separates step two into two by i) sensing “swing and jab” and ii) 
explicitly asking the user to select the correct injection site from a randomly ordered list. In 
addition it senses for the injector being held the right way around. This means that while 
AllergiSense assesses the four step injection performance it reports out of six rather than out 
of four.  
 
Workload and self-reported usability. The NASA TLX (NASA, 2003) and the System 
Usability Scale (SUS) (Brooke, 2006) questionnaires were used for evaluation of workload 
and self-reported usability, respectively. NASA TLX questionnaires were used to quantify 
levels of mental, physical and temporal demands, and self-reported levels of performance, 
effort and frustration. Each scale has 21 vertical marks that divide it from 0 to 100 in 
increments of 5. Low demand levels could indicate that a task would be more likely to be 
successful in a real scenario (Brewster et al., 2003).The SUS questionnaire was used to 
provide a measure of perceived usability, covering aspects of acceptance, need for support, 
training and system complexity (Jones & Marsden, 2006; Preece, Rogers & Sharp, 2002).  
 
Self-efficacy. A self-efficacy questionnaire for adrenaline injection was created using a ten-
point scale as recommended in guidelines by Bandura (2006). The selection and phrasing of 
the questions was first reviewed by the clinical collaborator of the study, checked by another 
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senior allergy clinician and later by other 16 allergy specialists (allergy immunologists and 
trained allergy nurses) who rated the questions according to their importance.  
 
Usefulness, ease-of-use and attitudes towards use. Self-reported measures of usefulness, 
ease of use and willingness regarding use were collected from technology acceptance 
questionnaires (Davis, 1989).  
 
5.2.4 Materials 
The materials used in the three groups (subsequent to their clinically approved training 
outlined below) are summarised as follows: 
 
Paper (traditional care paper documentation). Participants in all groups received a paper copy 
of the EpiPen® AAI instruction leaflet (the instructions for use provided in the EpiPen® AAI 
patient information). This document provides information about injector use and step-by-step 
pictures for each of the four injection steps. Participants in the paper-only (control) group 
received only this information. Participants in the other groups had this material 
supplemented with AllergiSense materials as described below. 
 
AllergiSense without feedback. This was the AllergiSense smartphone system without the 
injection practice feedback functionality, i.e., not using wireless sensor data and not providing 
out-of-six feedback, but with smartphone AAI step-by-step instructions and an AAI usage 
video. Thus participants with AllergiSense without feedback were provided with the paper 
instructions (the same as the control paper group) supplemented with smartphone video (an 
instructional Epipen video produced by the manufacturers (and available online in the 
EpiPen® AAI website) and a step-by step tool (text + pictures as per paper steps). 
 
AllergiSense. This was the complete AllergiSense smartphone system using wireless sensor 
and providing out-of-six injection feedback. Thus, participants in this group were provided 
paper instructions (the same as the control paper group) supplemented with smartphone AAI 
step-by-step instructions and an AAI usage video (the same as the AllergiSense without 
feedback) and the mark out-of-six injection feedback.  
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5.2.5 Experimental procedure 
 
     People who elected to participate were randomised and allocated to one of the three 
groups. Block randomisation (Alman & Bland, 1999) was carried out in blocks of three 
people to keep groups balanced. Participants were allocated to groups on a first-come-first-
serve basis. On the day of the first session participants read and signed consent forms. They 
were then all provided with clinically approved training: an explanatory video about 
anaphylaxis and how to use an AAI (including demonstrations of correct use) delivered by the 
study’s clinical collaborator. Participants were then provided with the material/s appropriate 
to their group.  
 
   The experimental phase comprised two sessions. The tasks involved in these sessions are 
summarised in Figs 5.1 and 5.2. All sessions were video recorded. All injections were made 
with trainers fitted with wireless sensors and all this sensor data was logged. The sensor data 
from all demonstrated injections was used to assist subsequent assessment of injection 
performance. Only in the AllergiSense group was this data also used for smartphone feedback 
during the training. 
 
   In session one, participants were trained as described above then asked to demonstrate 
injections using the trainer. They then completed AAI self-efficacy questionnaires before 
using their allocated materials to practice three training injections before demonstrating 
another injection after which they completed another self-efficacy questionnaire and also a 
technology acceptance and an SUS questionnaire. 
 
   In session two, two weeks later, participants were recalled to demonstrate injections and 
complete the AAI self-efficacy questionnaire. They then retrained by practicing three 
injections with their allocated material/s before making a final demonstration and completing 
a NASA TLX questionnaire. 
 
   Only the participants in the AllergiSense group received feedback on their injection 
performance. No other feedback was provided to any participants until after the completion of 
session two of the experiment. All participants were informed that the experiment was not a 
                               
 Chapter 5. Evaluation of AllergiSense Adrenaline Injection Training Tools 
89 
 
first-aid course and that they should seek and follow clinical instruction and patient 
information regarding any future AAI use. All participants received a £10 Amazon voucher 








Fig. 5.1 Research procedure for session one (duration: 30 minutes) 
                               




Fig. 5.2 Research procedure for session two (two weeks after session one - duration: 30 
minutes). 
 
     The performance of all participants’ adrenaline injections was evaluated via video 
observation. An inter-rated test with an independent researcher was carried out with a sample 
of injections (Cohen’s Kappa > 0.8). Injection step differences were discussed and analysed 




     Sixty-three participants completed the two-week study. All were healthy participants and 





     Table 5.1 shows the number of people in each group that correctly completed the four 
injection steps. Although more people in the AllergiSense group performed all steps correctly 
after the initial training (i.e., in demonstration 1), there were no significant differences 
                                                          
2
 Significance level= 0.05 
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between groups: 5 vs 4 (p=0.707), 5 vs 7 (p=0.495) and 4 vs 7 (p=0.242). Similarly, after 
training in session 1 (i.e., in demonstration 2) although more people in the AllergiSense group 
correctly completed all the steps, there were no significant differences between the groups: 5 
vs 9 (χ
2
=1.714, p=0.19), 5 vs 10 (χ
2
=2.593,p=0.107) and 9 vs 10 (χ
2
=0.96,p=0.757). However, 
after training in session two significantly more people in the AllergiSense and AllergiSense 
without feedback groups completed the four steps correctly compared to the control (paper-
only) group: 6 vs 19 (χ
2
=16.701,p<0.001 ) 6 vs 14 (χ
2
=6.109,p=0.013) respectively, while the 
difference between AllergiSense and AllergiSense with feedback showed a trend towards 





Table 5.1 Primary outcome: Number of people correctly completing the four injection steps. 
  
     The number of people correctly completing the steps in the paper only group did not 
change significantly across the four demonstrations (p>0.05), i.e., there was no significant 
change in their injection ability despite the training opportunities. However, the AllergiSense 
group improved significantly, from 9 to 19, after training in session two: 
(χ
2
=10.714,p=0.013), and the AllergiSense without feedback group showed a trend towards 
significance: from 8 to 14 (χ
2
=3.436,p=0.064). For the two AllergiSense groups the number  
of errors made decreased with training. Only 3.1% of all errors (225) involved a failure to 
remove the safety cap and all of these occurred in demonstration 1. Not injecting with 
sufficient force comprised 24.9%, not holding the AAI trainer in place for 10 seconds 
comprised 19.1% and not massaging the injection site for 10 seconds comprised 52.9% of all 
errors.  
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   Table 5.2 shows the questionnaire results for self-efficacy, usefulness, ease-of-use, attitudes 
towards use, system usability and workload. Self-efficacy differences within groups were seen 
after training with their allocated material(s) in session one. The paper-only group increased 
from 7.5 to 8.5 (χ
2
=-1.405, p<0.001), the AllergiSense without feedback group increased from 
7.6 to 8.6 (χ
2
=-1.429, p<0.001) and the AllergiSense group increased from 7.1 to 8.5 
((F,2)=47.321, p<0.001). Self-efficacy remained high for the three groups for two weeks, and 
no significant differences were found between the three groups (p>0.05). 
 
Table 5.2 Secondary outcomes: Self-efficacy, usefulness, ease-of-use, attitudes towards use, 
system usability and workload 
  
          Participants in the AllergiSense and AllergiSense without feedback groups gave 
significantly higher average scores for the usefulness, the ease-of use and in the willingness to 
use their training materials compared to the paper-only group. Usefulness: paper vs 
AllergiSense without feedback (χ
2
=-14.167,p=0.012); paper vs AllergiSense (χ
2
=-
19.333,p=0.001); Ease-of-use: paper vs AllergiSense without feedback (χ
2
=-18.690,p=0.001); 
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paper vs AllergiSense (χ
2
=-15.667,p=0.005); Willingness towards use: paper vs 
AllergiSense without feedback (p<0.001) and paper vs AllergiSense (p<0.001)..  
 
     Also, both AllergiSense groups reported significantly higher system usability scores (SUS) 
than the paper-only group: paper vs AllergiSense without feedback (χ
2
=-20.810,p<0.001); 
paper vs AllergiSense (χ
2
=-18.190, p=0.001). While the workload was not significant 
different between groups ((χ
2
,2)=0.018, p=0.991).  
 
5.4 Discussion of results 
     The purpose of this study was to compare the three different materials. Results support the 
main hypothesis that smartphone tools supplementing traditional care paper documents could 
improve adrenaline injection training. There was no significant improvement in the paper-
only performance throughout the study. The results supporting the hypothesis are: i) the 
significant difference between the number of participants correctly completing all steps of 
their final demonstration in the paper only group (28.6%) vs. the two AllergiSense groups: 
(AllergiSense without feedback (66.7%) and AllergiSense (90.5%)) and ii) in the greater 
within group improvement of the AllergiSense groups in Session 2 (AllergiSense without 
feedback (from 38.1 % to 66.7%) and AllergiSense (from 42.9% to 90.5)) compared with the 
paper-only group (which actually deteriorated from 38.1% to 28.6%, i.e., from eight people to 
six injecting correctly). The improved results for AllergiSense could be a consequence of 
improved training through the implementation of mastery, vicarious and social experiences of 
self-efficacy in the smartphone tools with videos, step-by-step instructions and visual 
feedback. In comparison the paper instructions only provides limited modelling opportunity 
via text and pictures. 
 
    Results also appear to support other reports in the literature regarding the inadequacy of the 
current approach to adrenaline injection education (i.e., expert explanation and AAI 
demonstration), in particular that it does not monitor practice nor provide feedback and does 
nothing to encourage or support continuous practice. This was observed after the first 
demonstration in session one when, at best, only one third of people in the three groups could 
correctly complete all four steps of the injection (23.8%, 19% and 33.3% for control, 
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AllergiSense without feedback and AllergiSense, respectively). These very low results concur 
with other extremely poor findings reported in the literature, for example, Brown et al's. 
(2013) findings that only 15% of mothers could correctly use an AAI after being shown how 
to do it.   
 
   One interesting and unexpected result in the testing was the significant increase in self-
efficacy in the paper-only group after they first used their material for training. This increase 
was less than the increase for the AllergiSense groups but not significantly less. The paper-
only group retained their increased self-efficacy throughout the study despite the lack of any 
significant improvement in their performance. This was exemplified at the end of session two 
by one paper-only participant who expressed surprise for each and all of the demonstrated 
injections they had made incorrectly. Bandura (2012) has reported in the literature that 
improved self-efficacy in the absence of improved performance indicates a problem in the 
system. Perhaps then, the experiment revealed something of the problem with the current 
system, i.e., that in the absence of monitoring and feedback people have elevated self-efficacy 
based on incorrect assumptions about their mastery skills. This could have several 
consequences, not least the lack of motivation for continuous practice. 
 
      Secondary outcome results showed participants reported no significant differences in 
workload for the three different materials. Interestingly, compared to the paper-only group 
both AllergiSense groups scored significantly better for usefulness and ease-of-use of their 
materials and also reported significantly more willingness towards use. Additionally, average 
self-reported usability scores for AllergiSense were very positive. The paper-only participants 
reported, according to (Bangor, Kortum & Miller, 2008:592) definitions, a marginally 
acceptable SUS score of 68.45 (between OK and good), while the SUS score for AllergiSense 
without feedback was 86.31 and was 82.74 for AllergiSense (both between good and 
excellent).  
  
      Self-efficacy results showed that adrenaline injection self-efficacy improved after the first 
training session and then was not significantly different two weeks later. Perhaps if 
participants had been recalled six weeks or six months later these self-efficacy results might 
be substantially different. Further work involving longer-term studies is recommended to 
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validate the injection training self-efficacy questionnaire and to investigate how self-efficacy 
and adrenaline injection skills attenuate over time and how these are impacted by the training 
materials used.  
 
5.5 Summary 
     This chapter presented a randomised, controlled, pre-post study to compare smartphone 
tools for anaphylaxis management to the paper instructions used in traditional care. Although 
the study was limited to healthy participants simulating adrenaline injections with an AAI 
trainer, it provided useful insights into how smartphone tools and wireless sensors could 
supplement traditional care paper documents and positively affect injection performance in 
training and user self-efficacy. 
 
                               











     This chapter provides results of the evaluation of AllergiSense by clinical staff. The reason 
for conducting this study was to ascertain the expert opinion of allergy specialists about 
AllergiSense and, more generally, to smartphone technology designed to support anaphylaxis 
management, and particularly, to support adrenaline injection training.  
 
   The following section explains the research procedure, the research authorisations and the 
participant profiles. Later, results are presented and discussed. Finally, a summary of the 
chapter is provided. 
  
6.2 Methods 
      
6.2.1 Research procedure 
     After signing consent forms clinical staff participants were provided with an introduction 
to the research and demonstrations in the use of the AllergiSense system. Each participant was 
then provided with an AllergiSense system for a one-week evaluation period after which a 
short semi-structured interview was carried out to receive their feedback. The systems (the 
smartphone, AAI trainers and mobile application software) were clearly labelled as research 
prototypes for evaluation and not for clinical use. The semi-structured interviews were audio 
recorded for analysis purposes. The interview questions asked the participants about their 
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previous experience with smartphone apps, and their opinions of the potential benefits, 
limitations or difficulties relevant to technology solutions for anaphylaxis management and to 
AllergiSense in particular. One researcher performed the interview and a second researcher 
assisted in taking notes. After the interview the two researchers made a summary of the 
session and identified significant themes. Later, an analysis of the recorded audio was 
performed to further clarify the main themes and ideas discussed. 
 
6.2.2 Research authorisations 
     This study required commitment to legal and regulatory processes. Before starting the study 
a risk assessment was performed and approved by the School of Electronic, Electrical and 
Systems Engineering and a research protocol was submitted and approved by the Science, 
Technology, Engineering and Mathematics Ethical Review Committee of the University of 
Birmingham UK (ERN_13-1496). Funding was provided by The Anaphylaxis Campaign’s 
Small Grant Scheme (04-13-LHM) and liability insurance was provided by the University of 
Birmingham (RG_14-090). The Leicester Royal Infirmary (University Hospitals of Leicester 
NHS Trust) agreed to provide a home base for the study and the researcher obtained 
certification (a good clinical practice certificate) and access permissions (a research passport).  
 
Table 6.1 Participants’ profile. 
Participant 
(Age interval) 
Clinical status (gender) Smartphone use 
1 (50-60) Allergy clinician (male) 
Reported having an iPhone and using mobile apps such as news 
and sports. Considered himself having moderate experience 
with smartphone (limited to Internet use and apps) 
2 (30-40) Allergy clinician (male) 
Reported using an iPhone and many apps such as BBC iPlayer, 
and audible train times. Considered himself having moderate 
smartphone experience (i.e. use of web browser and apps). 
3 (40-50) Allergy nurse (female) 
Reported using a Sony smartphone and communication apps 
(e.g. Skype and WhatsApp) but considered herself a beginner in 
smartphone app use. 
 
6.2.3 Participants 
     Two allergy clinicians and an allergy nurse participated in the AllergiSense evaluation. 
They were senior clinical allergy staff of the Leicester Royal Infirmary. Their profiles are 
described in Table 6.1. Participants reported using smartphones and smartphone apps. They 
considered themselves as having low to moderate experience with smartphones (limited to 
communication functionalities, and Internet and apps use). 
                               






     The study was carried out at the Leicester Royal Infirmary, a medical facility located in the 
English Leicester of England. Leicester is located in the centre of England; it has a total 
population of 329,839, of which 33.6% are foreign born (UK Census, 2011). Leicester Royal 
Infirmary has 890 beds and provides accident and emergency services.  The Children's 
Hospital has an allergy clinic (NHS, 2014) staffed with research-active senior allergy 
clinicians.  
 
     The clinical staff agreed to have a group interview one week after receiving AllergiSense. 
The interview lasted 1.5 hours and took place in the Paediatric Department of the Leicester 
Royal Infirmary. An allergy clinician and the allergy nurse attended the full interview, the 
second allergy specialist (the senior of the two) arrived half way through. However, he was 
provided with extra time to review the missing questions. The three clinicians answered all 
the questions. 
 
     The following discussion themes summarise the analysed recorded audio. They are: 
experience with smartphone apps, challenges in anaphylaxis management, how clinicians 
envisaged the use and delivery of those tools in the future, who could take the associated 
responsibility of the tools, how AllergiSense technology could be used by anaphylactic 
people, barriers that may affect the adoption of AllergiSense, using AllergiSense to tele-
monitor people’s injections skills, and finally, the advantages and disadvantages of 
AllergiSense and suggestions for improvement.  
 
Experience with smartphone apps. One participant expressed that he did not use apps 
frequently but that he had a smartphone, so he knew how to use them. Other participants 
declared using apps such as the BNF (British National Formulary) medical guidelines which 
is an app that provides guidance for prescribing, dispensing and administering prescribed 
drugs, and that they had downloaded some anaphylaxis apps for personal interests (e.g., Jext® 
and React), but mentioned that some of apps were difficult to find online (e.g., React app is 
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available in a web browser but not available for download). One allergy clinician mentioned 
medical apps as valuable references. 
 
Challenges in anaphylaxis management. Clinical staff mentioned that they considered two 
main issues as the main challenges in anaphylaxis management: anaphylaxis symptoms 
recognition and the management and use of AAIs. They mentioned that the recognition of 
symptoms, even after receiving explanations, was a difficult task for clinicians, paramedics 
and patients. An example was cited of a child in a school having only tingling lips (a very 
mild symptom) had been injected with three AAIs.  
 
     In regard to AAI use and management clinical staff highlighted that patients often do not 
carry AAIs and often do not use their AAIs when they need to, or otherwise delay their use. 
They also explained that possible reasons were a lack of confidence in the use of AAI, that 
patients were scared of using AAIs in the clinic for practice and outside the clinic for 
emergencies, maybe because they think that using an AAI could cause harm instead of a 
benefit.  Furthermore, interviewees highlighted that patients with prescribed AAIs often 
arrived at the clinic not knowing how to use them. This was often when their GPs (i.e., 
general practitioners or family doctors) had prescribed them but nobody had showed the 
patients how to use them. It was also pointed out in the interview that many medical students 
and clinicians do not know how to use AAIs because their courses do not include information 
on AAI use and management. In summary, carriage of AAI, recognition of symptoms and 
treating of anaphylaxis were considered issues to be addressed in anaphylaxis management. 
 
How clinicians envisaged the use of smartphone tools for anaphylaxis management in 
the future. Clinicians expressed that smartphone tools could be useful in an allergy clinic as 
“aid memoires” for patients, and making the clinic more efficient and more interactive. They 
said that injection training tools could be used for training medical staff (e.g., nurses), 
childminders and other people. Thus, through the feedback about their injection technique, 
people could be more attentive to training (interviewees expressed their desire to train other 
people with AllergiSense training tools). They also mentioned that outside the clinic, 
smartphone tools can have a certain role to inform patients, carers and relatives because a lot 
of people have a smartphone. They also suggested that there might be a dynamic process 
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where the tools could be renewed to avoid users, especially children, getting bored and not 
using them anymore. 
 
How clinicians imagine the delivery of this technology in the future. First of all they 
mentioned that distribution is a difficult issue because if the tools are tailored to one AAI 
manufacturer, they will be limited to their product. Secondly, clinical staff imagined GPs 
providing basic training to patients and carers and recommending them to download the app 
to learn how to use their prescribed AAI in a safe way. They highlighted that injection 
training tools could be a useful resource in that way since, usually, GPs make the diagnosis 
and then prescribe an AAI, but they have limited time to train patients.  
 
Who could take the associated responsibility in the maintenance of smartphone 
applications supporting anaphylaxis management. Clinical staff suggested that ideally the 
responsibility should be shared in a partnership among patients, carers, patient's support 
groups, national societies, representatives from schools and a group to coordinate the work. In 
addition, they suggested that there should be meetings twice or three times a year to verify 
how matters were evolving and improving. 
 
How AllergiSense technology could be used by anaphylactic people. Clinical staff said 
that some families could take the tools very seriously and that the tools will be very useful, for 
example, in training other people such as grandparents and babysitters. They also highlighted 
that AllergiSense could supplement the materials people have outside the clinic, where the 
role of AllergiSense would be to promote better management and the proper and timely use of 
AAIs. They also discussed if AllergiSense may have an impact in improving carriage and 
usage of AAIs. 
 
Barriers that may affect the adoption of AllergiSense tools. Interviewees mentioned that 
they did not see major barriers because AllergiSense tools would be easy to use, but that if 
patients were asked to purchase the tools, that could be, potentially, a barrier. Moreover, they 
mentioned that AllergiSense integrated many functionalities, thus additional information 
about the tools should be provided to understand their goals and know how and when to use 
them. They said the tools should be in English, but they could support other languages, 
                               
 Chapter 6. Clinician Evaluation 
101 
 
especially Asian languages such as Urdu, Indi and Arabic. They mentioned that many of their 
patients or carers were non-English speakers.  
 
Using AllergiSense to tele-monitor people's injection skills. Clinical staff said that they 
have used technology to tele-monitor people with diabetes. But that in anaphylaxis 
management they would not think it would be appropriate, due to privacy issues, to “police” 
patients’ skills. They mentioned that people could supplement their traditional training, 
outside the clinic, with AllergiSense, using it as a self-help tool and that it could also be 
useful inside the clinic to help with training while people wait for their appointments. 
 
How AllergiSense may support anaphylaxis management challenges. Clinical staff said 
that AllergiSense tools can be used to train novice people or as a reminder service for AAI 
practice, for example, they explained that the injection training tool could provide a good 
reinforcement and useful feedback about the injection steps to avoid possible mistakes. Also 
they pointed out that the injection training tool could be useful as an educational mechanism 
for medical students to provide them a "ground floor" about how to use an AAI because they 
will have, eventually, to prescribe AAIs to patients. Interviewees also mention that 
AllergiSense tool could help as a way to call emergency services promptly without dialling, 
so that patients and carers would have a sense of confidence that "they are not exactly on their 
own". They also expressed that AllergiSense could be a tool to address the fear factor that 
people have on AAI use.  
 
AllergiSense advantages and disadvantages and suggestions for improvement. 
Participants provided many useful, interesting and insightful ideas for improvement. They 
mentioned that the AAI injection training tool with the sensing unit as a reminding service 
was useful, they liked the ticks, crosses and stars to provide feedback about the steps of the 
training injection, which was considered a novel way to provide injection training. They also 
liked the idea of having a button that dials the 999 emergency number and the text messages 
to emergency contacts. However, they said that the information contained in the videos could 
be improved (the videos were produced by the Anaphylaxis Campaign and the EpiPen® AAI 
manufacturer). There were also suggestions to improve usability issues including not having 
different paths of information in the emergency tools and avoiding repetition in the “what to 
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do” tool. They said that a good addition could be the detection of the thumb on top of the AAI 
trainer device and the addition of a talking voice tool that calls emergency services (because 
people experiencing an anaphylactic reaction can lose their voice) and talking voice that 
explains the steps of the injection. In addition they suggested improving the reliability of the 
injection sensing for injections done when lying down (this condition was omitted from the 
training data). They also mentioned that a note should be added to the emergency information 
tools saying that an AAI can be injected through the trousers. Training reminders and the use 
of scenarios that provide aids for education were also suggested.  
 
6.4 Discussion 
     Four major findings were found in this study: First, clinicians expressed that smartphone tools 
for anaphylaxis management could be used to train people in AAI use inside and outside the clinic 
supplementing the traditional care system. Second, that AllergiSense tools could support patients 
and carers in the day-to-day anaphylaxis management and in emergency situations. Third, that 
medical staff and medical students could be trained with the tools implemented in AllergiSense 
(as training the trainers). And four, that there are no major barriers to adoption of the technology 
because people have already smartphones.  
 
     This study was, however, limited to a qualitative evaluation with three clinical staff 
participants in a one-week intervention. Nevertheless, the feedback was positive and insightful 
ideas about the future use of the tools were identified. Allergy specialists suggested that further 
work should evaluate the effects of those tools with healthy participants such as medical students 
and further work should consider studier with a larger number of clinicians. 
 
6.5 Summary 
     This chapter presented the opinions and attitudes of clinical staff about the tools 
implemented in AllergiSense after having the system (smartphone and sensing unit) for one 
week. The opinions and suggestions collected in a semi-structured interview were positive. 
They highlighted that those tools could encourage AAI carriage and use, and expressed their 
willingness towards the use of the technology in clinical settings and outside the clinic, for 
example, training medical staff, medical students, patients, carers, relatives, school teachers 
and baby sitters and supporting patients and carers in emergencies. 
                               






Conclusions and Further Work 
 
  
     The contribution of this thesis is three-fold: i) it defined tools for the support of 
anaphylaxis management; ii) it provided evidence about the ability of smartphone tools to 
improve AAI training and positively affect injection self-efficacy; and iii) it provided 
evidence of support from expert clinical evaluation regarding use and deployment. The 
research questions were: 
What assistive smartphone tools have potential to supplement anaphylaxis 
management? The thesis addressed this question in two ways: i) with multi-stage prototyping 
that showed that step-by-step tools supporting adrenaline injection may be more effective than 
the traditional care system alone. And ii) through the more substantial design and evaluation 
of AllergiSense which provided evidence of significant benefit and also received positive 
opinions from three allergy specialists.  
  
Could a smartphone tool improve adrenaline injection performance in training and 
positively influence self-efficacy? The results presented in the thesis showed that healthy 
participants using smartphone tools for injection training had significantly better performance 
than participants using traditional care paper documents alone. Furthermore, the results 
showed that participants using the technology had improved levels of self-efficacy that better 
reflected their actual performance, in comparison with paper-only participants that did not 
improve in their performance and had misguided perceptions of self-efficacy. 
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What is the clinical evaluation of specialists regarding the use and deployment of such 
tools?  Interviews with three clinicians that had AllergiSense smartphone tools for one week 
provided positive evidence about the potential for their use in the clinic and also in the 
community. They also expressed encouraging attitudes towards the use and deployment of 
smartphone applications for anaphylaxis management. They posited that such applications 
could supplement the traditional care system to train people in AAI use both inside and 
outside the clinic, supporting patients and carers in day-to-day anaphylaxis management and 
also in emergency situations. They also recommended that medical staff and medical students 
be trained with the tools implemented in AllergiSense (i.e., training the trainers) and reported 
that there were no major barriers to adoption given the ubiquity of smartphones amongst 
patients, carers and clinical staff.  
7.1 Conclusions 
     Anaphylaxis management has been a neglected subject in pervasive healthcare research. 
There are just a few simple anaphylaxis “apps” for which, like the majority of health-related 
“apps”, evaluation is not reported in the literature. Despite the demonstrated potential of 
pervasive healthcare technology and the breath of applications reported in the literature, there 
is comparative neglect for allergy and, in particular, for anaphylaxis, a condition which has 
increased worldwide to near epidemic prevalence. Although in other pervasive health 
applications there has often been an element of technology imposition which can present 
barriers to adoption, for anaphylaxis management this would be minimal since anaphylactic 
people and their carers already carry mobile phones (increasingly smartphones with built-in 
GPS) to call emergency services and they already carry AAIs. 
 
   This thesis has considered the difficulties associated with both technological prototyping 
and formal clinical trial evaluation. The clinical proof-of-concept prototyping proposed by 
Bardram (2008) provides a compromise between the two but still sets a very high goal, at 
least in terms of ethics and formal permissions, by recommending longitudinal studies with 
real users. The methodology developed and used in the design of AllergiSense has not been 
reported in the literature and is tentatively proposed as an incremental improvement for 
pervasive healthcare development. The methodology incorporates participatory design with 
embedded self-efficacy sources to develop a near-clinical proof-of-concept prototype, i.e., a 
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prototype tested by healthy participants but designed, tested and evaluated with clinical 
collaboration. This testing and evaluation provides results that can help support a case for 
further longer-term testing and testing with other larger groups of healthy participants, e.g., 
medical students. With positive outcomes a good case could then be made for testing with real 
patients.   
    
   The results of this research suggest that pervasive healthcare research has significant 
potential to support anaphylaxis management for people with anaphylaxis and their carers. In 
addition, clinician evaluation feedback identified further potential to support the training and 
education of medical students, practicing clinicians, health workers, childminders and school 
staff.  
 
   Experimental results from AllergiSense testing with healthy participants supported the main 
hypothesis that smartphone tools supplementing traditional care paper documents could 
improve the adrenaline injection performance in training and AAI self-efficacy. These 
improved results could be a consequence of improved training materials resulting from 
grounding of the design in self-efficacy as a behavioural change theory. AllergiSense included 
the implementation of mastery, vicarious and social experience sources of self-efficacy. In 
comparison the paper-only participants had only a limited modelling source of self-efficacy 
via text and pictures. Very possibly without realising it, participatory design focus group 
attendees asked for tools that could enhance levels of self-efficacy. Of course, people might 
intuitively ask for pictures or videos so that they can more easily copy (model) something 
they need to do. This suggests that participatory design in pervasive healthcare might more 
naturally ground solutions in self-efficacy theory, or at least help with contributing some 
sources of self-efficacy. These can then be enhanced further by the designer purposefully 
adding self-efficacy sources to tools (like the feedback injection tool in AllergiSense) that 
support the user requirements but might not have been explicitly proposed in the participatory 
design process.  
 
   Secondary outcome results showed participants reported no significant differences in 
workload for the different materials and interestingly, compared to the paper-only group both 
AllergiSense groups scored significantly better for usefulness and ease-of-use of their 
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materials and also reported significantly more willingness towards use. Additionally, average 
self-reported usability scores for AllergiSense were very positive. These results suggest really 
good potential usability for the technology. 
 
   Test results appeared to support other reports in the literature regarding the inadequacy of 
the current approach to adrenaline injection education, i.e., expert explanation and AAI 
demonstration and then documents for on-going support. In particular that the current 
approach does not monitor practice nor provide feedback and does nothing to encourage or 
support continuous practice. The increased level of self-efficacy in people using the 
traditional system in the control group was interesting and not expected, and it was not 
compatible with their performance. They retained this increased self-efficacy throughout the 
study despite the lack of any significant improvement in their performance. This could be a 
consequence of the lack of monitoring and feedback and it suggests that people were unable 
to identify their own errors and assessed their competence on incorrect assumptions about 
their mastery skills. This could have severe consequences, not least increased complacency 
and a lack of motivation for continuous practice. 
 
7.2 Further work 
    Since anaphylaxis management with smartphone tools has been neglected, the amount of 
research that could be undertaken is vast. There is so much that could be done and so little 
that has been done. In every aspect of the work presented here there is scope for much more 
contribution. Over 2% of children are now anaphylactic in the UK and the most common 
allergen, peanuts, is not generally outgrown. This new generation will need support in the 
management of their anaphylaxis. 
 
    This thesis was limited to short-term evaluations with healthy participants in training scenarios. 
The clinician evaluation was limited to qualitative evaluation with three clinical staff participants 
in a one-week intervention. Although the results and feedback were positive, the clinical 
recommendation is that further work is needed to evaluate the tools with healthy participants such 
as medical students and with a larger number of clinicians in patient settings. Further work is also 
needed to populate solutions with content and define tools aimed at supporting symptom 
recognition and allergen avoidance. Further work could also consider the issues of 
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responsibility for the support and maintenance of the technology and the information 
contained within it. In addition, further work is needed for the creation and validation of self-
efficacy questionnaires for anaphylaxis management and adrenaline injection and, 
importantly, much further work is needed for evaluation of tools in longitudinal studies with 
patients in and outside the clinic. Finally, future research could investigate how to improve 
injection sensing for training and perhaps also prototype new “smart” AAI designs with 
emergency sensing.  
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AllergiSense Sensing Unit 
 
Components: 
 Arduino Pro Mini 328 3.3V/8Mhz 
 Triple Axis Analogue Accelerometer Breakout - ADXL335 
 Coin Cell Battery Holder Breakout - 24.5mm   
 Coin Cell Battery Rechargeable - 24.5mm 
 USB micro connector 





 This program amends generic code (adding additional input and sensing) to read an analogue 
ADXL3xx accelerometer and communicate the acceleration intensity to a Bluetooth paired device 
using Serial Port Profile (SPP). The original code was created on 2 Jul 2008 by David A. Mellis 
modified 30 Aug 2011 by Tom Igoe, which code is in the public domain. 
http://www.arduino.cc/en/Tutorial/ADXL3xx 
 
 The circuit: 
 analog 0: x-axis 
 analog 1: y-axis 
 analog 2: a-axis 







//configure Bluetooth Serial port 
                               
 Appendix 3. AllergiSense Sensing Unit 
179 
 
// Pin 10 Arduino_vRX to BlueSmirf_Tx,          
// Pin 11 Arduino_vTX to BlueSmirf_Rx 
 
SoftwareSerial BTSerial(10, 11); 
 
//Connection between the accelerometer and the Arduino Pro Mini 
 
const int xpin = A0;                  // x-axis of the accelerometer 
const int ypin = A1;                  // y-axis 
const int zpin = A2;                  // z-axis  
const int capButton = 2;              // push button placed under  
                                         the blue safety cap (AAI  
                   trainer device) 
 












// initialise serial communications between Arduino and PC at 9600 //baud for debugging purposes 
 
  Serial.begin(9600); 
   
//Send a string from the Arduino to the PC using the Micro UART (Rx, //Tx) 
 
  Serial.println("Hi PC");  
 
//Set up a pull up internal resistor to sense a push button placed //under the blue safety cap of the AAI 
device. 
//resistor activated: switch open=>pin 2 = 1(Vcc);  
//switch closed =>pin 2 = 0(GND) 
 
pinMode(capButton,INPUT_PULLUP);  
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  if(BTSerial.available() >0) 
  { 
            
      ch=BTSerial.read();  //Read serial port 
      Serial.print(ch);    //For debugging send it to the PC if it  
                           //is available 
      int i=0;             //declare an index to control the 
                           //the number of each row of data 
       
//if an ‘x’ is received, start sensing acceleration data and send them to a Bluetooth paired 
device. 
 
      if(ch == 'x')           
{ 
        do 
        {         
           
          X=analogRead(xpin);    //Read X axis and start creating 
      // the output.  
// the output will look like D[i]=X,Y,Z,S. this is going to //be processed in the paired 
device 
 
          BTSerial.print(" D["); 
          BTSerial.print(i); 
          BTSerial.print("]="); 
          BTSerial.print(X); 
          BTSerial.print(","); 
  
          Y=analogRead(ypin);    //Read Y axis and add it to the              
  // output. 
 
          BTSerial.print(Y); 
          BTSerial.print(","); 
 
          Z=analogRead(zpin);     //Read Z axis and add it to the               // 
output. 
 
          BTSerial.print(Z); 
          BTSerial.print(","); 
           
          S=digitalRead(capButton); //Read the status of the blue  
                                    //safety cap button and  
                                    //add it to the output. 
 
          BTSerial.println(S);      // read the input pin: 
                                        
          i++;       //increase index  
           
          if(i>3500)          //Maximum number of rows to send=3500 
           ch='y';     //This is 90 seconds of data 
                     
                   
          if(BTSerial.available() >0) 
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          { 
             ch=BTSerial.read();         //real serial port 
             Serial.print(ch);           //Debugging  
          } 
        }while (ch!='y');  //if a ‘y’ is received from the paired  
//device stop sending data. 
        i=0;          //re-start index 
      }                
  } 
 
 





                               











                               




(Seven features, classifying only 3 types of motion, injection in direction of the Y-axis, 12 
training injections) 
 
=== Run information === 
Scheme:       weka.classifiers.trees.J48 -C 0.25 -M 2 
Relation:     FeaturesaCSVYaxis 
Instances:    187  
Attributes:   7 
              yaverage 
              ysd 
              yMax 
              ymin 
              dYaverage 
              yMax-ymin 
              Class 
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Test mode:    10-fold cross-validation 
 
=== Classifier model (full training set) === 
 
J48 pruned tree 
------------------ 
 
dYaverage <= 1.933061: still (108.0/1.0) 
dYaverage > 1.933061 
|   ymin <= 153 
|   |   dYaverage <= 37.37602: jab (19.0/3.0) 
|   |   dYaverage > 37.37602: moving (4.0/1.0) 
|   ymin > 153 
|   |   ysd <= 12.774451 
|   |   |   yMax-ymin <= 50: moving (12.0) 
|   |   |   yMax-ymin > 50 
|   |   |   |   dYaverage <= 4.609694: still (3.0) 
|   |   |   |   dYaverage > 4.609694 
|   |   |   |   |   yMax-ymin <= 99: moving (13.0/2.0) 
|   |   |   |   |   yMax-ymin > 99: still (2.0) 
|   |   ysd > 12.774451: moving (26.0) 
 
Number of Leaves  :  8 
 
Size of the tree :  15 
 
 
Time taken to build model: 0 seconds 
 
=== Stratified cross-validation === 
=== Summary === 
 
Correctly Classified Instances         164               87.7005 % 
Incorrectly Classified Instances        23               12.2995 % 
Total Number of Instances              187      
 
=== Confusion Matrix === 
   a   b   c   <-- classified as 
  48   2   4 |   a = moving 
   5  12   0 |   b = jab 
  10   2 104 |   c = still 
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Self-efficacy Questionnaire for Adrenaline Injection 
     The aim of this questionnaire was to create an instrument to measure self-efficacy for 
adrenaline injection. The questions were based on the needs expressed by focus group 
participants presented in chapter 4 of this thesis, the manufacturer’s EpiPen® AAI 
instructions and from sources of self-efficacy (mastery, modelling, social persuasion and 
physiological factors). The questions were selected (from a long list of candidate questions) 
by the clinical collaborator and checked by another senior allergy clinician. 
Please read each statement and rate with an ‘X’ your degree of confidence in the scale that goes 
from 0 to 10.  
Statement 
Not at all                Moderately                       Totally 
confident               confident                       confident 
I---I                               I---I                                  I---I 
1. I am confident that I know what 
anaphylaxis is. 
0 1 2 3 4 5 6 7 8 9 10 
2. I am confident that I know the possible 
causes of anaphylaxis. 
0 1 2 3 4 5 6 7 8 9 10 
3. I am confident that I know the 
symptoms of anaphylaxis. 
0 1 2 3 4 5 6 7 8 9 10 
4. I am confident that I know the 
treatment for anaphylaxis. 
0 1 2 3 4 5 6 7 8 9 10 
5. I am confident that I can recognise an 
adrenaline Auto-Injector. 
0 1 2 3 4 5 6 7 8 9 10 
6. I am confident that I know how to use 
an adrenaline Auto-Injector. 
0 1 2 3 4 5 6 7 8 9 10 
7. I am confident that I know the 
difference between an Auto-Injector 
trainer and a real Auto-Injector. 
0 1 2 3 4 5 6 7 8 9 10 
8. I am confident that I know what 
medication an Auto-Injector contains. 
0 1 2 3 4 5 6 7 8 9 10 
9. I am confident that I know why an 
Auto-Injector should always be carried. 
0 1 2 3 4 5 6 7 8 9 10 
10. I am confident that I know if an Auto-
Injector can be injected through 
clothing. 
0 1 2 3 4 5 6 7 8 9 10 
11. I am confident that I could correctly 
use an Auto-Injector in an allergic 
emergency. 
0 1 2 3 4 5 6 7 8 9 10 
12. I am confident that I can correctly use 
an Auto-Injector trainer in a practice 
session. 
0 1 2 3 4 5 6 7 8 9 10 
13. I am confident that I can demonstrate 
how to hold an Auto-Injector. 
0 1 2 3 4 5 6 7 8 9 10 
14. I am confident that I can identify the 
safety release cap. 
0 1 2 3 4 5 6 7 8 9 10 
15. I am confident that I know how to 
remove the safety release cap. 
0 1 2 3 4 5 6 7 8 9 10 
16. I am confident that I can identify the 
end of the Auto-Injector where the 
0 1 2 3 4 5 6 7 8 9 10 
                               




Not at all                Moderately                       Totally 
confident               confident                       confident 
I---I                               I---I                                  I---I 
needle comes out. 
17. I am confident that I can demonstrate 
which Auto-Injector end should point 
towards the injection site. 
0 1 2 3 4 5 6 7 8 9 10 
18. I am confident that I can identify the 
correct injection site. 
0 1 2 3 4 5 6 7 8 9 10 
19. I am confident that I can apply the 
correct force when injecting. 
0 1 2 3 4 5 6 7 8 9 10 
20. I am confident that I can demonstrate 
the correct time required to hold the 
injector in the injection site. 
0 1 2 3 4 5 6 7 8 9 10 
21. I am confident that I can demonstrate 
for how long the injection site should be 
massaged. 
0 1 2 3 4 5 6 7 8 9 10 
22. I am confident that I know what to do 
in an emergency after completing an 
injection. 
0 1 2 3 4 5 6 7 8 9 10 
23. I am confident that I know when to call 
emergency services 
0 1 2 3 4 5 6 7 8 9 10 
24. I am confident that I know when to 
use a second Auto-Injector. 
0 1 2 3 4 5 6 7 8 9 10 
25. I am confident that I know who to ask 
to obtain more information about Auto-
Injectors. 
0 1 2 3 4 5 6 7 8 9 10 
26. I am confident that I have access to 
information beyond the printed 
manufacturer instructions. (e.g., I have 
access to instructional videos or 
automatic injector expiry date 
reminders). 
0 1 2 3 4 5 6 7 8 9 10 
27. I am confident that I can tell other 
people how and when to use an Auto-
Injector.  
0 1 2 3 4 5 6 7 8 9 10 
28. I am confident that I am prepared to 
retrain periodically (or as needed).  
0 1 2 3 4 5 6 7 8 9 10 
29.  I am confident that I can perform a 
successful adrenaline injection by 
copying a demonstration I have 
observed. 
0 1 2 3 4 5 6 7 8 9 10 
30. I am confident that I could learn from 
expert guidance or feedback about how 
to use an Auto-Injector correctly. 
0 1 2 3 4 5 6 7 8 9 10 
31. I am confident that I can obtain 
feedback to improve adrenaline 
0 1 2 3 4 5 6 7 8 9 10 
                               




Not at all                Moderately                       Totally 
confident               confident                       confident 
I---I                               I---I                                  I---I 
injection skills. 
32. I am confident that I would not feel 
very anxious when demonstrating an 
adrenaline injection. 
0 1 2 3 4 5 6 7 8 9 10 
33. I am confident that I would not feel 
very anxious when injecting adrenaline 
in a real emergency situation. 
0 1 2 3 4 5 6 7 8 9 10 
34. I am confident that I would inject 
correctly in an emergency even if I was 
very anxious. 
0 1 2 3 4 5 6 7 8 9 10 
35. I am confident that I would feel 
confident when demonstrating an 
adrenaline injection. 
0 1 2 3 4 5 6 7 8 9 10 
36. I am confident that I would feel 
confident when injecting adrenaline in a 
real emergency situation. 
0 1 2 3 4 5 6 7 8 9 10 
 
 
Questionnaire Reliability  
Table A5.1 Cronbach’s alpha for the internal reliability of the self-efficacy questionnaire. 
 
Expert Rating     
 The questions were reviewed and rated according to their importance (0:not important to 
5:Very important) by 15 allergy nurses, 2 allergy clinicians and 1 trained carer. 
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Table A5.2 Experts who reviewed and rated the questions 
 
Figure A5.1 Expert ratings 
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System Usability Scale (Brooke, 2006) 
Scale: 1 – 5; 1:Strongly disagree, 5:Strongly agree 
 
Paper group: 
1. I think that I would like to use paper documents frequently.     
2. I found paper documents unnecessarily complex.     
3. I thought paper documents were easy to use.                        
4. I think that I would need the support of a person to be able to use paper documents.  
5. I found the information in paper documents was well integrated.   
6. I thought there was too much inconsistency in paper documents.  
7. I would imagine that most people would learn to use paper documents  very quickly. 
8. I found paper documents very complicated to use.   
9. I felt very confident using paper documents. 
10. I needed to learn a lot of things before I could get going with paper documents. 
 
AllergiSense groups: 
1. I think that I would like to use AllergiSense frequently.      
2. I found AllergiSense unnecessarily complex.     
3. I thought AllergiSense was easy to use.                        
4. I think that I would need the support of a technical person to be able to use AllergiSense. 
5. I found the various functions in AllergiSense were well integrated. 
6. I thought there was too much inconsistency in AllergiSense 
7. I would imagine that most people would learn to use AllergiSense very quickly   
8. I found AllergiSense very complicated to use. 
9. I felt very confident using AllergiSense. 
10. I needed to learn a lot of things before I could get going with AllergiSense.   
 
Usefulness (Davis, 1989) 
Scale 
likely I________I________I________I________I________I________I________I unlikely 
                               extremely        quite          slightly        neither       slightly         quite         extremely 
Paper group: 
1. Using paper documents would enable me to know how to accomplish the injection of 
adrenaline more quickly 
2. Using paper documents would improve my adrenaline injection performance 
3. Using paper documents would increase my adrenaline injection productivity 
4. Using paper documents would enhance my effectiveness on injecting adrenaline 
5. Using paper documents would make it easier to inject adrenaline 




                               




1. Using AllergiSense would enable me to know how to accomplish the injection of 
adrenaline more quickly. 
2. Using AllergiSense would improve my adrenaline injection performance. 
3. Using AllergiSense would increase my adrenaline injection productivity. 
4. Using AllergiSense would enhance my effectiveness in injecting adrenaline. 
5. Using AllergiSense would make it easier to inject adrenaline. 
6. I would find AllergiSense useful to inject adrenaline. 
 
Injection performance: Doing the tasks of injecting adrenaline. 
Injection productivity: The capacity of producing a good injection with low effort. 
Injection effectiveness: The ability to do an adrenaline injection successfully. 
 
Ease of Use (Davis, 1989) 
Scale 
likely I________I________I________I________I________I________I________I unlikely 
                               extremely        quite          slightly        neither       slightly         quite         extremely 
Paper group 
1. Learning to inject adrenaline using paper documents would be easy for me. 
2. I would find it easy to get paper documents to do what I want it to do (inject adrenaline). 
3. My interaction with paper documents to inject adrenaline would be clear and 
understandable. 
4. I would find paper documents to be flexible to interact with. 
5. It would be easy for me to become skilful at using paper documents to inject adrenaline. 
6. I would find paper documents easy to use to inject adrenaline. 
AllergiSense groups 
1. Learning to inject adrenaline using AllergiSense would be easy for me. 
2. I would find it easy to get AllergiSense to do what I want it to do (inject adrenaline). 
3. My interaction with AllergiSense to inject adrenaline would be clear and understandable. 
4. I would find AllergiSense to be flexible to interact with. 
5. It would be easy for me to become skilful at using AllergiSense to inject adrenaline. 
6. I would find AllergiSense easy to use to inject adrenaline. 
 
Attitudes Towards Use (Davis, 1989) 
1. Using paper documents to know how to inject adrenaline is 
 
Wise I________I________I________I________I________I________I________I Foolish 
                                 extremely      quite         slightly          neither       slightly       quite          extremely 
 
Negative I________I________I________I________I________I________I________I Positive 
                                    extremely      quite         slightly      neither          slightly        quite         extremely 
 
Harmful I________I________I________I________I________I________I________I Beneficial 
                                   extremely      quite         slightly      neither       slightly          quite        extremely 
 
Good I________I________I________I________I________I________I________I Bad 
                                     extremely      quite         slightly      neither           slightly         quite        extremely 
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2. If paper documents were to be available to know how to inject adrenaline, I would use 
them frequently 
 
Disagree I________I________I________I________I________I________I________I Agree 
                                 strongly      quite         slightly      neither       slightly       quite        strongly 
 
 
Whenever possible, I intend to use paper documents to know how to inject adrenaline 
 
Disagree I________I________I________I________I________I________I________I Agree 




1. Using AllergiSense to know how to inject adrenaline is 
 
Wise I________I________I________I________I________I________I________I Foolish 
                                 extremely      quite         slightly      neither         slightly         quite        extremely 
 
Negative I________I________I________I________I________I________I________I Positive 
                                    extremely      quite         slightly      neither          slightly       quite          extremely 
 
Harmful I________I________I________I________I________I________I________I Beneficial 
                                 extremely      quite         slightly        neither            slightly       quite        extremely 
 
Good I________I________I________I________I________I________I________I Bad 




2. If AllergiSense were to be available to know how to inject adrenaline, I would use it 
frequently 
 
Disagree I________I________I________I________I________I________I________I Agree 
                                        strongly      quite         slightly      neither           slightly        quite          strongly 
 
 
Whenever possible, I intend to use AllergiSense to know how to inject adrenaline 
 
Disagree I________I________I________I________I________I________I________I Agree 





NASAS TLX (NASA, 2003) 
We want to measure the workload you experienced in the tasks. Workload can have different factors. 
The factors we are measuring are: 
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RATING SCALE DEFINITIONS 
Factor Endpoints Descriptions 
MENTAL DEMAND Low/High How much mental demand was required (e.g., thinking, 
deciding, looking, searching) 
Was the task easy or demanding, simple or complex? 
PHYSICAL DEMAND Low/High How much physical activity was required (e.g., pushing, 
pulling, turning, controlling) 
Was the task easy or demanding, restful or laborious? 
TEMPORAL DEMAND Low/High How much time pressure did you feel due to the rate or pace at 
which the tasks elements occurred? 
Was the pace of the task slow and leisurely or rapid and 
frantic? 
PERFORMANCE Perfect/ Failure How successful do you think you were in accomplishing the 
goals of the task? 
EFFORT Low/High How hard did you have to work (mentally and physically) to 
accomplish your level of performance? 
FRUSTRATION Low/High How insecure, discourage, irritated, stressed and annoyed 
versus gratified, content and relaxed did you feel during the 
task? 
 
Template suggested by the author: 
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     The factors that affect the workload of the task may have a different weight. For example, a task 
might be difficult or hard because it must be completed quickly (high temporal demand) or because 
the intensity of mental or physical demand required was high.  
From the following pairs please select the factor that represents the more important contributor 
to the demands of injecting adrenaline.  
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Semi-Structured Interview with Clinicians 
1.  Smartphone technology and mobile apps. 
1.1 Do you use any Smartphone healthcare application? 
1.2 What has it been your experience with these applications? 
2. Questions about anaphylaxis challenges that need to be supported (by any means). 
2.1 As a clinician, what are the main challenges you observe in the management of anaphylaxis? 
2.2 What are the challenges reported by your patients and their carers? 
3. Implications of Smartphone tools in anaphylaxis management. 
3.1 After using AllergiSense for a few days, how do you envisage these types of tools could be 
used in the future? 
3.2 How do you imagine this technology could be delivered in the future? (e.g., distributed by a 
clinic or by manufacturers)? 
3.4 Who do you think could or should take the associated responsibilities? 
3.5 How do you imagine this technology would be used by anaphylactic people? 
3.6 Can you identify any factors that can influence the adoption of this technology?  
3.7 What barriers can you see in the adoption of Smartphone applications for anaphylaxis 
management? 
3.6 Do you imagine that data could be reported to or from AllergiSense?  For example, injection 
scores could be sent to the allergy clinic, or the clinic could automatically send reminders about 
AAI expiry date? (What data would be useful?) 
3.7 How do you imagine AllergiSense could be used in different settings? (e.g., in the clinic, in 
schools, training relatives, people of different age) 
3.8 Do you think AllergiSense could improve anaphylaxis management supplementing traditional 
care? 
4. At the beginning of the interview you mentioned challenges in anaphylaxis management. How 
can you see those challenges being supported by AllergiSense? 
5. From the tools implemented in AllergiSense, what do you find most useful? 
6. From the tools implemented in AllergiSense, what do you find less important? 
7. How do you think AllergiSense could support patient self-efficacy?  
8. Overall what are the advantages of AllergiSense? 
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1:not                                                                                  10:Very 
very                                                                                     useful 
useful 
The expiry date list 
 
1          2          3         4          5         6         7        8        9        10 
The videos 1          2          3         4          5         6         7        8        9        10 
The adrenaline injection 
training (step by step) 
1          2          3         4          5         6         7        8        9        10 
The adrenaline injection 
training (with the Epipen 
trainer sensor) 
1          2          3         4          5         6         7        8        9        10 
Emergency what to do 1          2          3         4          5         6         7        8        9        10 
Injection steps 1          2          3         4          5         6         7        8        9        10 
Contact messages (sending 
automatic texts) 
1          2          3         4          5         6         7        8        9        10 
Call 999 1          2          3         4          5         6         7        8        9        10 
 
11. Would you suggest any additions or modifications to the tools in AllergiSense? 
 
12. Do you have any other comments or suggestions you would like to share with us? 
 
 
                               









                               





The independent researcher is a lecturer at the University of Birmingham. 
Training with one participant, four injections. 









                               




Adrenaline Injection Errors  
(Number of people) 
 
 
 
 
 
 
 
 
